---
title: "Parameters and Calculations Reference"
subtitle: "Comprehensive Documentation of Economic Model Variables"
format:
  html:
    toc: true
    toc-depth: 3
    number-sections: true
    code-fold: true
---

# Overview

This appendix provides comprehensive documentation of all parameters and calculations used in the economic analysis of the 1% Treaty and Decentralized FDA.

**Total parameters**: 491

- External sources (peer-reviewed): 148
- Calculated values: 294
- Core definitions: 49

# External Data Sources {#sec-external}

Parameters sourced from peer-reviewed publications, institutional databases, and authoritative reports.

::: {.callout-tip icon=false collapse=false}
## Accidents Death Rate {#sec-accidents_death_rate}

**Value**: 62.3

Accidental/unintentional injury death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Alzheimers Death Rate {#sec-alzheimers_death_rate}

**Value**: 27.7

Alzheimer's disease death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Antibiotics Life Extension Years {#sec-antibiotics_life_extension_years}

**Value**: 10

Life extension from antibiotics (conservative mid-range from 5-23 years)

**Source**: [life-expectancy-gains-medical-advances](../references.qmd#life-expectancy-gains-medical-advances)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Market Return Pct {#sec-average_market_return_pct}

**Value**: 10%

Average annual stock market return (10%)

**Source**: [average-stock-market-return](../references.qmd#average-stock-market-return)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Average Us Hourly Wage {#sec-average_us_hourly_wage}

**Value**: $30

Average US hourly wage

**Source**: [average-us-hourly-wage](../references.qmd#average-us-hourly-wage)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Baseline Lives Saved Annual Millions {#sec-baseline_lives_saved_annual_millions}

**Value**: 12

Baseline annual lives saved by pharmaceuticals (conservative aggregate)

**Source**: [who-global-health-estimates-2024](../references.qmd#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Biometric Verification Cost Per User High Usd {#sec-biometric_verification_cost_per_user_high_usd}

**Value**: $0

Biometric KYC verification cost at medium volume

**Source**: [kyc-biometric-verification-costs-2024](../references.qmd#kyc-biometric-verification-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Biometric Verification Cost Per User Low Usd {#sec-biometric_verification_cost_per_user_low_usd}

**Value**: $0

Biometric KYC verification cost at high volume (300M+ scale)

**Source**: [kyc-biometric-verification-costs-2024](../references.qmd#kyc-biometric-verification-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Book Reading Speed Wpm {#sec-book_reading_speed_wpm}

**Value**: 200

Average reading speed (conservative for non-fiction)

**Source**: [average-reading-speed](../references.qmd#average-reading-speed)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cancer Death Rate {#sec-cancer_death_rate}

**Value**: 147

Cancer death rate (all cancers)

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Cardiovascular Death Rate {#sec-cardiovascular_death_rate}

**Value**: 201

Cardiovascular disease death rate (heart disease + stroke)

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Annual Value Total {#sec-caregiver_annual_value_total}

**Value**: $600B

Total annual value of unpaid caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Count Us {#sec-caregiver_count_us}

**Value**: 38M

Number of unpaid caregivers in US

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Hours Per Month {#sec-caregiver_hours_per_month}

**Value**: 20

Average monthly hours of unpaid family caregiving in US

**Source**: [average-family-caregiving-hours](../references.qmd#average-family-caregiving-hours)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Hours Per Week Avg {#sec-caregiver_hours_per_week_avg}

**Value**: 25.5

Average weekly hours of unpaid caregiving (25-26 hours/week)

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Value Per Hour {#sec-caregiver_value_per_hour}

**Value**: $17

AARP valuation of caregiving per hour

**Source**: [unpaid-caregiver-hours-economic-value](../references.qmd#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Caregiver Value Per Hour Simple {#sec-caregiver_value_per_hour_simple}

**Value**: $25

Estimated replacement cost per hour of caregiving

**Source**: [caregiver-replacement-cost](../references.qmd#caregiver-replacement-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Childhood Vaccination Annual Benefit {#sec-childhood_vaccination_annual_benefit}

**Value**: $15B

Estimated annual global economic benefit from childhood vaccination programs (measles, polio, etc.)

**Source**: [/knowledge/economics/economics.qmd#better-than-the-best-charities](../references.qmd#/knowledge/economics/economics.qmd#better-than-the-best-charities)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Childhood Vaccination Roi {#sec-childhood_vaccination_roi}

**Value**: 13

Return on investment from childhood vaccination programs

**Source**: [childhood-vaccination-roi](../references.qmd#childhood-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Active Trials {#sec-current_active_trials}

**Value**: 10,000

Current active trials at any given time (3-5 year duration)

**Source**: [active-clinical-trials-baseline](../references.qmd#active-clinical-trials-baseline)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Clinical Trial Participation Rate {#sec-current_clinical_trial_participation_rate}

**Value**: 0.06%

Current clinical trial participation rate (0.06% of population)

**Source**: [clinical-trial-participants](../references.qmd#clinical-trial-participants)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Disease Patients Global {#sec-current_disease_patients_global}

**Value**: 2.40B

Global population with chronic diseases

**Source**: [global-burden-disease-2-4-billion](../references.qmd#global-burden-disease-2-4-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Drug Approvals Per Year {#sec-current_drug_approvals_per_year}

**Value**: 50

Average annual new drug approvals globally

**Source**: [global-new-drug-approvals-50-annually](../references.qmd#global-new-drug-approvals-50-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Patient Eligibility Rate {#sec-current_patient_eligibility_rate}

**Value**: 0.2%

Current patient eligibility rate for clinical trials (0.2%)

**Source**: [clinical-trial-eligibility-rate](../references.qmd#clinical-trial-eligibility-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trials Per Year {#sec-current_trials_per_year}

**Value**: 3,300

Current global clinical trials per year

**Source**: [global-clinical-trials-per-year](../references.qmd#global-clinical-trials-per-year)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trial Abandonment Rate {#sec-current_trial_abandonment_rate}

**Value**: 40%

Current trial abandonment rate (40% never complete)

**Source**: [clinical-trial-abandonment-rate](../references.qmd#clinical-trial-abandonment-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trial Completion Rate {#sec-current_trial_completion_rate}

**Value**: 60%

Current trial completion rate (60%)

**Source**: [clinical-trial-completion-rate](../references.qmd#clinical-trial-completion-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Current Trial Slots Available {#sec-current_trial_slots_available}

**Value**: 5.00M

Total trial slots available for 2.4B sick people

**Source**: [global-trial-participant-capacity](../references.qmd#global-trial-participant-capacity)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Defense Lobbying Annual Billions {#sec-defense_lobbying_annual_billions}

**Value**: $127M

Annual defense industry lobbying spending

**Source**: [lobbying-spend-defense](../references.qmd#lobbying-spend-defense)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Diabetes Death Rate {#sec-diabetes_death_rate}

**Value**: 22.4

Diabetes death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Diabetes Treatment Monthly Cost {#sec-diabetes_treatment_monthly_cost}

**Value**: $500

Average monthly cost of diabetes treatment per patient

**Source**: [diabetes-treatment-costs](../references.qmd#diabetes-treatment-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier Education Investment {#sec-economic_multiplier_education_investment}

**Value**: 2.1

Economic multiplier for education investment (2.1x ROI)

**Source**: [economic-multiplier-education](../references.qmd#economic-multiplier-education)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier Healthcare Investment {#sec-economic_multiplier_healthcare_investment}

**Value**: 4.3

Economic multiplier for healthcare investment (4.3x ROI)

**Source**: [economic-multiplier-healthcare](../references.qmd#economic-multiplier-healthcare)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier Infrastructure Investment {#sec-economic_multiplier_infrastructure_investment}

**Value**: 1.6

Economic multiplier for infrastructure investment (1.6x ROI)

**Source**: [economic-multiplier-infrastructure](../references.qmd#economic-multiplier-infrastructure)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Economic Multiplier Military Spending {#sec-economic_multiplier_military_spending}

**Value**: 0.6

Economic multiplier for military spending (0.6x ROI)

**Source**: [economic-multiplier-military](../references.qmd#economic-multiplier-military)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Efficacy Lag Years {#sec-efficacy_lag_years}

**Value**: 8.2

Regulatory delay for efficacy testing (Phase II/III) post-safety verification

**Source**: [bio-clinical-development-2021](../references.qmd#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Cost Per Life Avg {#sec-givewell_cost_per_life_avg}

**Value**: $4.50K

GiveWell average cost per life saved across top charities

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Cost Per Life Max {#sec-givewell_cost_per_life_max}

**Value**: $5.50K

GiveWell cost per life saved (Against Malaria Foundation)

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Givewell Cost Per Life Min {#sec-givewell_cost_per_life_min}

**Value**: $3.50K

GiveWell cost per life saved (Helen Keller International)

**Source**: [givewell-cost-per-life-saved](../references.qmd#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Conflict Deaths Active Combat {#sec-global_annual_conflict_deaths_active_combat}

**Value**: 234K

Annual deaths from active combat worldwide

**Source**: [acled-2024](../references.qmd#acled-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Conflict Deaths State Violence {#sec-global_annual_conflict_deaths_state_violence}

**Value**: 2,700

Annual deaths from state violence

**Source**: [ucdp-2024](../references.qmd#ucdp-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Conflict Deaths Terror Attacks {#sec-global_annual_conflict_deaths_terror_attacks}

**Value**: 8,300

Annual deaths from terror attacks globally

**Source**: [gtd-2024](../references.qmd#gtd-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Environmental Damage Conflict {#sec-global_annual_environmental_damage_conflict}

**Value**: $100B

Annual environmental damage and restoration costs from conflict

**Source**: [war-environmental-damage-costs](../references.qmd#war-environmental-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Communications Conflict {#sec-global_annual_infrastructure_damage_communications_conflict}

**Value**: $298B

Annual infrastructure damage to communications from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Education Conflict {#sec-global_annual_infrastructure_damage_education_conflict}

**Value**: $234B

Annual infrastructure damage to education facilities from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Energy Conflict {#sec-global_annual_infrastructure_damage_energy_conflict}

**Value**: $422B

Annual infrastructure damage to energy systems from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Healthcare Conflict {#sec-global_annual_infrastructure_damage_healthcare_conflict}

**Value**: $166B

Annual infrastructure damage to healthcare facilities from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Transportation Conflict {#sec-global_annual_infrastructure_damage_transportation_conflict}

**Value**: $487B

Annual infrastructure damage to transportation from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Infrastructure Damage Water Conflict {#sec-global_annual_infrastructure_damage_water_conflict}

**Value**: $268B

Annual infrastructure damage to water systems from conflict

**Source**: [war-infrastructure-damage-costs](../references.qmd#war-infrastructure-damage-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Lives Saved By Med Research {#sec-global_annual_lives_saved_by_med_research}

**Value**: 4.20M

Annual lives saved by medical research globally

**Source**: [medical-research-lives-saved-annually](../references.qmd#medical-research-lives-saved-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Lost Economic Growth Military Spending {#sec-global_annual_lost_economic_growth_military_spending}

**Value**: $2.72T

Annual lost economic growth from military spending opportunity cost

**Source**: [military-spending-opportunity-cost](../references.qmd#military-spending-opportunity-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Lost Human Capital Conflict {#sec-global_annual_lost_human_capital_conflict}

**Value**: $300B

Annual lost productivity from conflict casualties

**Source**: [war-lost-human-capital](../references.qmd#war-lost-human-capital)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Military Spending Infrastructure 2024 {#sec-global_annual_military_spending_infrastructure_2024}

**Value**: $520B

Global military spending on infrastructure in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Military Spending Intelligence 2024 {#sec-global_annual_military_spending_intelligence_2024}

**Value**: $282B

Global military spending on intelligence in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Military Spending Ops Maintenance 2024 {#sec-global_annual_military_spending_ops_maintenance_2024}

**Value**: $580B

Global military spending on operations and maintenance in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Military Spending Personnel 2024 {#sec-global_annual_military_spending_personnel_2024}

**Value**: $682B

Global military spending on personnel in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Military Spending Procurement 2024 {#sec-global_annual_military_spending_procurement_2024}

**Value**: $654B

Global military spending on procurement in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Psychological Impact Costs Conflict {#sec-global_annual_psychological_impact_costs_conflict}

**Value**: $232B

Annual PTSD and mental health costs from conflict

**Source**: [war-psychological-impact-costs](../references.qmd#war-psychological-impact-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Refugee Support Costs {#sec-global_annual_refugee_support_costs}

**Value**: $150B

Annual refugee support costs (108.4M refugees Ã— $1,384/year)

**Source**: [refugee-support-costs](../references.qmd#refugee-support-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Trade Disruption Currency Conflict {#sec-global_annual_trade_disruption_currency_conflict}

**Value**: $57.4B

Annual trade disruption costs from currency instability

**Source**: [war-trade-disruption-costs](../references.qmd#war-trade-disruption-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Trade Disruption Energy Price Conflict {#sec-global_annual_trade_disruption_energy_price_conflict}

**Value**: $125B

Annual trade disruption costs from energy price volatility

**Source**: [war-trade-disruption-costs](../references.qmd#war-trade-disruption-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Trade Disruption Shipping Conflict {#sec-global_annual_trade_disruption_shipping_conflict}

**Value**: $247B

Annual trade disruption costs from shipping disruptions

**Source**: [war-trade-disruption-costs](../references.qmd#war-trade-disruption-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Trade Disruption Supply Chain Conflict {#sec-global_annual_trade_disruption_supply_chain_conflict}

**Value**: $187B

Annual trade disruption costs from supply chain disruptions

**Source**: [war-trade-disruption-costs](../references.qmd#war-trade-disruption-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Annual Veteran Healthcare Costs {#sec-global_annual_veteran_healthcare_costs}

**Value**: $200B

Annual veteran healthcare costs (20-year projected)

**Source**: [global-veteran-healthcare-costs](../references.qmd#global-veteran-healthcare-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Clinical Trials Spending Annual {#sec-global_clinical_trials_spending_annual}

**Value**: $83B

Annual global spending on clinical trials

**Source**: [global-clinical-trials-market-2024](../references.qmd#global-clinical-trials-market-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Clinical Trial Market Annual {#sec-global_clinical_trial_market_annual}

**Value**: $100B

Global clinical trial market size

**Source**: [global-clinical-trial-market](../references.qmd#global-clinical-trial-market)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Cost Per Refugee Per Year Average {#sec-global_cost_per_refugee_per_year_average}

**Value**: $1.38K

Average annual cost per refugee globally

**Source**: [unhcr-refugee-cost-per-year](../references.qmd#unhcr-refugee-cost-per-year)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Daily Deaths Curable Diseases {#sec-global_daily_deaths_curable_diseases}

**Value**: 150K

Daily deaths from curable diseases globally

**Source**: [global-daily-deaths-curable-diseases](../references.qmd#global-daily-deaths-curable-diseases)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Disease Economic Burden Annual {#sec-global_disease_economic_burden_annual}

**Value**: $109T

Total economic burden of disease globally (lost productivity, mortality, disability)

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Education For All Cost {#sec-global_education_for_all_cost}

**Value**: $30B

Global cost to achieve universal education

**Source**: [unesco-education-for-all-cost](../references.qmd#unesco-education-for-all-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Forcibly Displaced People 2023 {#sec-global_forcibly_displaced_people_2023}

**Value**: 108M

Global forcibly displaced people in 2023

**Source**: [unhcr-global-displacement-2023](../references.qmd#unhcr-global-displacement-2023)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Gdp 2023 {#sec-global_gdp_2023}

**Value**: $89.5T

Global GDP in 2023 for comparison

**Source**: [global-gdp](../references.qmd#global-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Gdp 2024 {#sec-global_gdp_2024}

**Value**: $111T

Global GDP in 2024

**Source**: [global-gdp](../references.qmd#global-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Healthcare Spending Annual 2024 {#sec-global_healthcare_spending_annual_2024}

**Value**: $9.80T

Global healthcare spending in 2024

**Source**: [global-health-spending](../references.qmd#global-health-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Med Research Spending {#sec-global_med_research_spending}

**Value**: $67.5B

Global government medical research spending

**Source**: [global-government-medical-research-spending](../references.qmd#global-government-medical-research-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Military Spending Annual 2024 {#sec-global_military_spending_annual_2024}

**Value**: $2.72T

Global military spending in 2024

**Source**: [global-military-spending](../references.qmd#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Nuclear Weapons Annual Budget Increase {#sec-global_nuclear_weapons_annual_budget_increase}

**Value**: $42B

Annual increase in global nuclear weapons budget

**Source**: [global-nuclear-weapons-budget-increase](../references.qmd#global-nuclear-weapons-budget-increase)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Population 2024 Billions {#sec-global_population_2024_billions}

**Value**: 8.00B

Global population in 2024

**Source**: [global-population-8-billion](../references.qmd#global-population-8-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Population Activism Threshold Pct {#sec-global_population_activism_threshold_pct}

**Value**: 3.5%

Critical mass threshold for social change (3.5% rule)

**Source**: [3-5-percent-rule-social-change](../references.qmd#3-5-percent-rule-social-change)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Poverty Eradication Cost Total {#sec-global_poverty_eradication_cost_total}

**Value**: $1.00T

Total cost to eradicate global poverty

**Source**: [world-bank-poverty-eradication](../references.qmd#world-bank-poverty-eradication)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Global Symptomatic Disease Treatment Annual {#sec-global_symptomatic_disease_treatment_annual}

**Value**: $8.20T

Annual global spending on symptomatic disease treatment

**Source**: [disease-economic-burden-109t](../references.qmd#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Kidney Disease Death Rate {#sec-kidney_disease_death_rate}

**Value**: 13.1

Kidney disease death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Liver Disease Death Rate {#sec-liver_disease_death_rate}

**Value**: 13

Liver disease death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Lobbying Roi Defense {#sec-lobbying_roi_defense}

**Value**: 1,813

Return on investment for defense lobbying ($1,813 returned per $1 spent)

**Source**: [defense-lobbying-roi](../references.qmd#defense-lobbying-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Lobbyist Salary Max Millions {#sec-lobbyist_salary_max_millions}

**Value**: $2.00M

Maximum annual lobbyist salary range

**Source**: [average-lobbyist-salary](../references.qmd#average-lobbyist-salary)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Lobbyist Salary Min K {#sec-lobbyist_salary_min_k}

**Value**: $500K

Minimum annual lobbyist salary range

**Source**: [average-lobbyist-salary](../references.qmd#average-lobbyist-salary)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Lobbyist Salary Typical K {#sec-lobbyist_salary_typical_k}

**Value**: $500K

Typical annual lobbyist salary for comparison

**Source**: [average-lobbyist-salary](../references.qmd#average-lobbyist-salary)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Measles Vaccination Roi {#sec-measles_vaccination_roi}

**Value**: 14

Return on investment from measles (MMR) vaccination programs

**Source**: [measles-vaccination-roi](../references.qmd#measles-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Medical Facility Hourly Room Cost {#sec-medical_facility_hourly_room_cost}

**Value**: $500

Average hourly cost of medical facility room

**Source**: [hospital-room-costs](../references.qmd#hospital-room-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Mental Health Grants Annual Millions {#sec-mental_health_grants_annual_millions}

**Value**: $500M

Annual mental health research grants total

**Source**: [mental-health-research-funding](../references.qmd#mental-health-research-funding)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Mental Health Productivity Loss Per Capita {#sec-mental_health_productivity_loss_per_capita}

**Value**: $2.00K

Annual productivity loss per capita from mental health issues (beyond treatment costs)

**Source**: [mental-health-productivity-loss](../references.qmd#mental-health-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Petition Signature Cost Per Verified 2024 {#sec-petition_signature_cost_per_verified_2024}

**Value**: $15

Average cost per verified petition signature in 2024 US campaigns

**Source**: [ballot-measure-signature-costs-2024](../references.qmd#ballot-measure-signature-costs-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 1 Safety Duration Years {#sec-phase_1_safety_duration_years}

**Value**: 2.3

Phase I safety trial duration

**Source**: [bio-clinical-development-2021](../references.qmd#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 3 Trial Cost Max Millions {#sec-phase_3_trial_cost_max_millions}

**Value**: $282M

Phase 3 trial total cost (maximum)

**Source**: [phase-3-cost-per-trial](../references.qmd#phase-3-cost-per-trial)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Phase 3 Trial Cost Min Millions {#sec-phase_3_trial_cost_min_millions}

**Value**: $20M

Phase 3 trial total cost (minimum)

**Source**: [phase-3-cost-per-trial](../references.qmd#phase-3-cost-per-trial)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Polio Vaccination Roi {#sec-polio_vaccination_roi}

**Value**: 39

Return on investment from sustaining polio vaccination assets and integrating into expanded immunization programs

**Source**: [polio-vaccination-roi](../references.qmd#polio-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Political Success Probability Conservative {#sec-political_success_probability_conservative}

**Value**: 0.1

Conservative estimate of political success probability (10%)

**Source**: [historical-treaty-adoption-rates](../references.qmd#historical-treaty-adoption-rates)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Political Success Probability Moderate {#sec-political_success_probability_moderate}

**Value**: 0.25

Moderate estimate of political success probability (25%)

**Source**: [historical-treaty-adoption-rates](../references.qmd#historical-treaty-adoption-rates)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Political Success Probability Optimistic {#sec-political_success_probability_optimistic}

**Value**: 0.5

Optimistic estimate of political success probability (50%)

**Source**: [historical-treaty-adoption-rates](../references.qmd#historical-treaty-adoption-rates)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Post Ww2 Military Cut Pct {#sec-post_ww2_military_cut_pct}

**Value**: 30%

Percentage military spending cut after WW2 (historical precedent)

**Source**: [post-ww2-military-demobilization](../references.qmd#post-ww2-military-demobilization)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Productivity Loss Per Affected Employee {#sec-productivity_loss_per_affected_employee}

**Value**: $4.80K

Annual productivity loss per affected employee (IBI 2024)

**Source**: [chronic-illness-productivity-loss-ibi](../references.qmd#chronic-illness-productivity-loss-ibi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Rare Diseases Count Global {#sec-rare_diseases_count_global}

**Value**: 7,000

Total number of rare diseases globally

**Source**: [95-pct-diseases-no-treatment](../references.qmd#95-pct-diseases-no-treatment)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Rare Disease Typical Patient Count {#sec-rare_disease_typical_patient_count}

**Value**: 500

Typical patient count for rare diseases

**Source**: [rare-disease-prevalence](../references.qmd#rare-disease-prevalence)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Recovery Trial Cost Per Patient {#sec-recovery_trial_cost_per_patient}

**Value**: $500

RECOVERY trial cost per patient

**Source**: [recovery-trial-cost-per-patient](../references.qmd#recovery-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment Early Adopters Usd {#sec-referral_payment_early_adopters_usd}

**Value**: $0

Referral payment for early adopters (first 10M, motivated believers)

**Source**: [paypal-dropbox-referral-case-studies](../references.qmd#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment Laggards Usd {#sec-referral_payment_laggards_usd}

**Value**: $2

Referral payment for laggards (200-280M, resistant)

**Source**: [paypal-dropbox-referral-case-studies](../references.qmd#paypal-dropbox-referral-case-studies)

*? Low confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment Late Majority Usd {#sec-referral_payment_late_majority_usd}

**Value**: $1

Referral payment for late majority (100-200M, skeptics)

**Source**: [paypal-dropbox-referral-case-studies](../references.qmd#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Referral Payment Mainstream Usd {#sec-referral_payment_mainstream_usd}

**Value**: $0

Referral payment for mainstream adopters (10-100M, pragmatists)

**Source**: [paypal-dropbox-referral-case-studies](../references.qmd#paypal-dropbox-referral-case-studies)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Refugee Lost Earning Potential Per Capita Annual {#sec-refugee_lost_earning_potential_per_capita_annual}

**Value**: $23.4K

Average annual lost earning potential per refugee

**Source**: [refugee-lost-earnings](../references.qmd#refugee-lost-earnings)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Respiratory Death Rate {#sec-respiratory_death_rate}

**Value**: 33.4

Chronic respiratory disease death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Smallpox Eradication Roi {#sec-smallpox_eradication_roi}

**Value**: 280

Return on investment from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](../references.qmd#smallpox-eradication-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Software Tool Monthly Cost Max {#sec-software_tool_monthly_cost_max}

**Value**: $2.00K

Maximum monthly cost for software tools/services

**Source**: [software-pricing-market-rates](../references.qmd#software-pricing-market-rates)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Software Tool Monthly Cost Min {#sec-software_tool_monthly_cost_min}

**Value**: $500

Minimum monthly cost for software tools/services

**Source**: [software-pricing-market-rates](../references.qmd#software-pricing-market-rates)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Standard Economic Qaly Value Usd {#sec-standard_economic_qaly_value_usd}

**Value**: $150K

Standard economic value per QALY

**Source**: [standard-qaly-value](../references.qmd#standard-qaly-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Standard Qalys Per Life Saved {#sec-standard_qalys_per_life_saved}

**Value**: 35

Standard QALYs per life saved (WHO life tables)

**Source**: [who-life-tables-qalys-per-life](../references.qmd#who-life-tables-qalys-per-life)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Sugar Subsidy Cost Per Person Annual {#sec-sugar_subsidy_cost_per_person_annual}

**Value**: $10

Annual cost of sugar subsidies per person

**Source**: [agricultural-subsidies](../references.qmd#agricultural-subsidies)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Switzerland Defense Spending Pct {#sec-switzerland_defense_spending_pct}

**Value**: 0.7%

Switzerland's defense spending as percentage of GDP (0.7%)

**Source**: [switzerland-defense-spending-gdp](../references.qmd#switzerland-defense-spending-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Switzerland Gdp Per Capita K {#sec-switzerland_gdp_per_capita_k}

**Value**: $93K

Switzerland GDP per capita

**Source**: [switzerland-gdp-per-capita](../references.qmd#switzerland-gdp-per-capita)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Terrorism Deaths 911 {#sec-terrorism_deaths_911}

**Value**: 2,996

Deaths from 9/11 terrorist attacks

**Source**: [911-deaths](../references.qmd#911-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Death Rate {#sec-total_death_rate}

**Value**: 722

Overall age-adjusted death rate

**Source**: [cdc-leading-causes-death](../references.qmd#cdc-leading-causes-death)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Total Medical Advances 1900 2000 {#sec-total_medical_advances_1900_2000}

**Value**: 35

Total life expectancy gain from all medical advances 1900-2000 (vaccines + hygiene + antibiotics)

**Source**: [life-expectancy-gains-medical-advances](../references.qmd#life-expectancy-gains-medical-advances)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Large Trial Size {#sec-traditional_large_trial_size}

**Value**: 1,000

Typical Phase 3 trial size

**Source**: [phase-3-trial-participant-numbers](../references.qmd#phase-3-trial-participant-numbers)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Phase2 Cost Per Patient High {#sec-traditional_phase2_cost_per_patient_high}

**Value**: $120K

Phase 2 cost per patient (high estimate)

**Source**: [clinical-trial-cost-per-patient](../references.qmd#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Phase2 Cost Per Patient Low {#sec-traditional_phase2_cost_per_patient_low}

**Value**: $40K

Phase 2 cost per patient (low estimate)

**Source**: [clinical-trial-cost-per-patient](../references.qmd#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Phase3 Cost Per Patient {#sec-traditional_phase3_cost_per_patient}

**Value**: $80K

Phase 3 cost per patient (median)

**Source**: [phase-3-cost-per-patient](../references.qmd#phase-3-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Phase3 Cost Per Patient Example 48K {#sec-traditional_phase3_cost_per_patient_example_48k}

**Value**: $48K

Example Phase 3 trial cost per patient ($48K)

**Source**: [clinical-trial-cost-per-patient](../references.qmd#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Phase3 Cost Per Patient Fda Example 41K {#sec-traditional_phase3_cost_per_patient_fda_example_41k}

**Value**: $41K

FDA cited Phase 3 cost per patient ($41K)

**Source**: [fda-clinical-trial-costs](../references.qmd#fda-clinical-trial-costs)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Traditional Small Trial Size {#sec-traditional_small_trial_size}

**Value**: 100

Typical Phase 2 trial size

**Source**: [phase-2-trial-participant-numbers](../references.qmd#phase-2-trial-participant-numbers)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Treatment Acceleration Years Current {#sec-treatment_acceleration_years_current}

**Value**: 17

Traditional FDA drug development timeline

**Source**: [fda-drug-approval-timeline](../references.qmd#fda-drug-approval-timeline)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Trial Cost Reduction Factor {#sec-trial_cost_reduction_factor}

**Value**: 82

Cost reduction factor demonstrated by RECOVERY trial

**Source**: [recovery-trial-82x-cost-reduction](../references.qmd#recovery-trial-82x-cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Typical Ceo Hourly Rate {#sec-typical_ceo_hourly_rate}

**Value**: $10K

Typical CEO hourly rate

**Source**: [ceo-compensation](../references.qmd#ceo-compensation)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Annual Drug Spending {#sec-us_annual_drug_spending}

**Value**: $360B

Annual US pharmaceutical spending

**Source**: [us-drug-spending-annual](../references.qmd#us-drug-spending-annual)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Chronic Disease Spending Annual {#sec-us_chronic_disease_spending_annual}

**Value**: $4.10T

US annual chronic disease spending

**Source**: [us-chronic-disease-spending](../references.qmd#us-chronic-disease-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Defense Budget Annual Billions {#sec-us_defense_budget_annual_billions}

**Value**: $877B

US defense budget in 2024

**Source**: [us-defense-budget-2024](../references.qmd#us-defense-budget-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Dot Value Of Statistical Life Millions {#sec-us_dot_value_of_statistical_life_millions}

**Value**: $13.6M

US Department of Transportation value of statistical life

**Source**: [us-dot-value-statistical-life](../references.qmd#us-dot-value-statistical-life)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Drug Price Multiplier Vs Peer Countries {#sec-us_drug_price_multiplier_vs_peer_countries}

**Value**: 2.78

US drug prices compared to peer countries multiplier

**Source**: [us-drug-prices-vs-peer-countries](../references.qmd#us-drug-prices-vs-peer-countries)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Median Salary {#sec-us_median_salary}

**Value**: $59.4K

US median salary in 2024

**Source**: [us-median-salary-2024](../references.qmd#us-median-salary-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Mental Health Cost Annual {#sec-us_mental_health_cost_annual}

**Value**: $350B

US mental health costs (treatment + productivity loss)

**Source**: [us-mental-health-cost](../references.qmd#us-mental-health-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Military Spending Pct Gdp {#sec-us_military_spending_pct_gdp}

**Value**: 3.5%

US military spending as percentage of GDP (2024)

**Source**: [us-military-budget-3-5-pct-gdp](../references.qmd#us-military-budget-3-5-pct-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Us Population 2024 {#sec-us_population_2024}

**Value**: 335M

US population in 2024

**Source**: [us-population-335m](../references.qmd#us-population-335m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Value Of Statistical Life {#sec-value_of_statistical_life}

**Value**: $10M

Value of Statistical Life (conservative estimate)

**Source**: [dot-vsl-13-6m](../references.qmd#dot-vsl-13-6m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Verification Conversion Rate Good Ux {#sec-verification_conversion_rate_good_ux}

**Value**: 85%

Identity verification completion rate with good UX (fintech data)

**Source**: [fintech-identity-verification-conversion-2024](../references.qmd#fintech-identity-verification-conversion-2024)

*âœ“ High confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Verification Conversion Rate Poor Ux {#sec-verification_conversion_rate_poor_ux}

**Value**: 50%

Identity verification completion rate with poor UX

**Source**: [fintech-identity-verification-conversion-2024](../references.qmd#fintech-identity-verification-conversion-2024)

*~ Medium confidence â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
## Vsl Epa Millions {#sec-vsl_epa_millions}

**Value**: $9.60M

EPA value of statistical life

**Source**: [epa-value-statistical-life](../references.qmd#epa-value-statistical-life)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Water Fluoridation Roi {#sec-water_fluoridation_roi}

**Value**: 23

Return on investment from water fluoridation programs

**Source**: [water-fluoridation-roi](../references.qmd#water-fluoridation-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Workforce Chronic Illness Prevalence {#sec-workforce_chronic_illness_prevalence}

**Value**: 78.4%

Workforce with at least one chronic condition (78.4%)

**Source**: [chronic-illness-workforce-productivity-loss](../references.qmd#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Workforce With Productivity Loss {#sec-workforce_with_productivity_loss}

**Value**: 28%

Percentage of workforce experiencing productivity loss from chronic illness (28%)

**Source**: [chronic-illness-workforce-productivity-loss](../references.qmd#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
## Ww2 Bond Return Pct {#sec-ww2_bond_return_pct}

**Value**: 4%

World War II war bond return percentage (4%)

**Source**: [ww2-war-bonds-return](../references.qmd#ww2-war-bonds-return)

*âœ“ High confidence*

:::

# Calculated Values {#sec-calculated}

Parameters derived from mathematical formulas and economic models.

::: {.callout-note icon=false collapse=false}
## Action Time Invest Minutes {#sec-action_time_invest_minutes}

**Value**: 10

Time to invest (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Action Time Recruit Minutes {#sec-action_time_recruit_minutes}

**Value**: 15

Time to recruit others (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Action Time Total Hours {#sec-action_time_total_hours}

**Value**: 0.45

Total action time in hours

$$
Hours = 27 / 60 = 0.45 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Action Time Total Minutes {#sec-action_time_total_minutes}

**Value**: 27

Total time for all three actions

$$
TotalTime = 2 + 10 + 15 = 27 \text{ minutes}
$$

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Action Time Vote Minutes {#sec-action_time_vote_minutes}

**Value**: 2

Time to vote (minutes)

**Methodology**: [../solution/wishocracy.qmd#action-steps](../solution/wishocracy.qmd#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Alzheimer Cure Bounty Estimate Billions {#sec-alzheimer_cure_bounty_estimate_billions}

**Value**: $10B

Estimated bounty value for Alzheimer's cure

**Methodology**: [Cure Bounty Estimation Model](#cure-bounty-estimates)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Drug Price Reduction Annual {#sec-benefit_drug_price_reduction_annual}

**Value**: $100B

Annual benefit from R&D savings passed to consumers

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#price-reduction](../appendix/dfda-cost-benefit-analysis.qmd#price-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Earlier Drug Access Annual {#sec-benefit_earlier_drug_access_annual}

**Value**: $300B

Annual benefit from 7-year drug access acceleration

**Methodology**: [../appendix/economic-value-of-accelerated-treatments.qmd](../appendix/economic-value-of-accelerated-treatments.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Medical Research Acceleration Annual {#sec-benefit_medical_research_acceleration_annual}

**Value**: $100B

Annual benefit from 115x research capacity increase

**Methodology**: [../appendix/research-acceleration-model.qmd](../appendix/research-acceleration-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Mental Health Annual {#sec-benefit_mental_health_annual}

**Value**: $75B

Annual benefit from mental health treatment gap reduction

**Methodology**: [../appendix/dfda-qaly-model.qmd#mental-health](../appendix/dfda-qaly-model.qmd#mental-health)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Prevention Annual {#sec-benefit_prevention_annual}

**Value**: $100B

Annual benefit from economic viability of prevention

**Methodology**: [../appendix/dfda-qaly-model.qmd#prevention](../appendix/dfda-qaly-model.qmd#prevention)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Rare Diseases Annual {#sec-benefit_rare_diseases_annual}

**Value**: $400B

Annual benefit from orphan drug viability

**Methodology**: [../appendix/dfda-qaly-model.qmd#rare-diseases](../appendix/dfda-qaly-model.qmd#rare-diseases)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Benefit Research And Development Savings Annual {#sec-benefit_research_and_development_savings_annual}

**Value**: $50B

Annual R&D savings benefit (alias for dFDA gross savings)

$$
R\&D_{savings} = \$50B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction](../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Book Reading Time Hours {#sec-book_reading_time_hours}

**Value**: 14.3

Time to read the entire book

$$
ReadTime = \frac{171,121 / 200}{60} \approx 14.3 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#time-investment](../solution/wishocracy.qmd#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Celebrity Endorsement Millions {#sec-campaign_celebrity_endorsement_millions}

**Value**: $15M

Celebrity and influencer endorsements

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Community Organizing Millions {#sec-campaign_community_organizing_millions}

**Value**: $30M

Community organizing and ambassador program budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Contingency Millions {#sec-campaign_contingency_millions}

**Value**: $50M

Contingency fund for unexpected costs

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Defense Conversion Millions {#sec-campaign_defense_conversion_millions}

**Value**: $50M

Defense industry conversion program

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Defense Lobbyist Budget Millions {#sec-campaign_defense_lobbyist_budget_millions}

**Value**: $50M

Budget for co-opting defense industry lobbyists

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Healthcare Alignment Millions {#sec-campaign_healthcare_alignment_millions}

**Value**: $35M

Healthcare industry alignment and partnerships

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Infrastructure Millions {#sec-campaign_infrastructure_millions}

**Value**: $20M

Campaign operational infrastructure

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Legal Ai Budget Millions {#sec-campaign_legal_ai_budget_millions}

**Value**: $50M

AI-assisted legal work budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Legal Defense Millions {#sec-campaign_legal_defense_millions}

**Value**: $20M

Legal defense fund

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Legal Work Millions {#sec-campaign_legal_work_millions}

**Value**: $60M

Legal drafting and compliance work

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Lobbying Eu Millions {#sec-campaign_lobbying_eu_millions}

**Value**: $40M

EU lobbying campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Lobbying G20 Millions {#sec-campaign_lobbying_g20_millions}

**Value**: $35M

G20 countries lobbying budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Lobbying Us Millions {#sec-campaign_lobbying_us_millions}

**Value**: $50M

US lobbying campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Media Budget Max Billions {#sec-campaign_media_budget_max_billions}

**Value**: $1.00B

Maximum mass media campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Media Budget Min Millions {#sec-campaign_media_budget_min_millions}

**Value**: $500M

Minimum mass media campaign budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Opposition Research Millions {#sec-campaign_opposition_research_millions}

**Value**: $25M

Opposition research and rapid response

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Phase1 Budget Millions {#sec-campaign_phase1_budget_millions}

**Value**: $200M

Phase 1 campaign budget (Foundation, Year 1)

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Phase2 Budget Millions {#sec-campaign_phase2_budget_millions}

**Value**: $500M

Phase 2 campaign budget (Scale & Momentum, Years 2-3)

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Pilot Programs Millions {#sec-campaign_pilot_programs_millions}

**Value**: $30M

Pilot program testing in small countries

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Platform Development Millions {#sec-campaign_platform_development_millions}

**Value**: $35M

Voting platform and technology development

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Regulatory Navigation Millions {#sec-campaign_regulatory_navigation_millions}

**Value**: $20M

Regulatory compliance and navigation

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Scaling Prep Millions {#sec-campaign_scaling_prep_millions}

**Value**: $30M

Scaling preparation and blueprints

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Staff Budget Millions {#sec-campaign_staff_budget_millions}

**Value**: $40M

Campaign core team staff budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Super Pac Budget Millions {#sec-campaign_super_pac_budget_millions}

**Value**: $30M

Super PAC campaign expenditures

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Tech Partnerships Millions {#sec-campaign_tech_partnerships_millions}

**Value**: $25M

Tech industry partnerships and infrastructure

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Treaty Implementation Millions {#sec-campaign_treaty_implementation_millions}

**Value**: $40M

Post-victory treaty implementation support

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Viral Content Budget Millions {#sec-campaign_viral_content_budget_millions}

**Value**: $40M

Viral marketing content creation budget

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Campaign Weekly Ad Cost K {#sec-campaign_weekly_ad_cost_k}

**Value**: $500K

Weekly advertising cost for campaigns

**Methodology**: [../economics/campaign-budget.qmd](../economics/campaign-budget.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Combined Peace Health Dividends Annual For Roi Calc {#sec-combined_peace_health_dividends_annual_for_roi_calc}

**Value**: $139B

Combined peace and health dividends for ROI calculation

$$
Combined = \$113.55B + \$50B = \$163.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#combined-dividends](../appendix/1-percent-treaty-cost-effectiveness.qmd#combined-dividends)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Completed Trials Multiplier Actual {#sec-completed_trials_multiplier_actual}

**Value**: 180

Actual completed trials multiplier (180x theoretical)

**Methodology**: [../appendix/research-acceleration-model.qmd#total-multiplier](../appendix/research-acceleration-model.qmd#total-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Completed Trials Multiplier Conservative {#sec-completed_trials_multiplier_conservative}

**Value**: 115

Conservative completed trials multiplier accounting for scale-up

$$
Multiplier_{conservative} = 115
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#conservative-multiplier](../appendix/research-acceleration-model.qmd#conservative-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Completed Trials Multiplier Theoretical Max {#sec-completed_trials_multiplier_theoretical_max}

**Value**: 560

Theoretical maximum research capacity multiplier (25Ã—10Ã—1.6Ã—1.4)

*Formula*: `RECRUITMENT_SPEED Ã— COMPLETION_SPEED Ã— COMPLETION_RATE Ã— FUNDING`

**Methodology**: [../appendix/research-acceleration-model.qmd#theoretical-maximum](../appendix/research-acceleration-model.qmd#theoretical-maximum)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Completion Rate Improvement Multiplier {#sec-completion_rate_improvement_multiplier}

**Value**: 1.6

Completion rate improvement (1.6x from 60% â†’ 95%)

$$
Completion_{mult} = \frac{0.95}{0.60} = 1.58 \approx 1.6
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#completion-rates](../appendix/research-acceleration-model.qmd#completion-rates)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Conservative Scenario Roi {#sec-conservative_scenario_roi}

**Value**: 189

Conservative scenario ROI (net benefit Ã· total costs)

$$
ROI_{conservative} = \$74.6B / \$0.393B = 190:1
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost Of Delay Deaths Per Second {#sec-cost_of_delay_deaths_per_second}

**Value**: 1.74

Preventable deaths per second from curable diseases

$$
Delay_{deaths} = \frac{150,000}{86,400} \approx 1.74
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-of-delay](../problem/cost-of-war.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost Of Delay Qaly Days Per Second {#sec-cost_of_delay_qaly_days_per_second}

**Value**: 8.04e-05

QALY-days lost per second of inaction

$$
Delay_{QALY} = \frac{925,610 / 365}{31,557,600} \approx 0.00008
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-of-delay](../problem/cost-of-war.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost Per Life Investor Funded {#sec-cost_per_life_investor_funded}

**Value**: $-7

Cost per life for investor-funded scenario

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Cost Per Life Opportunity Cost {#sec-cost_per_life_opportunity_cost}

**Value**: $-5

Cost per life counting military spending opportunity cost

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Current Completed Trials Per Year {#sec-current_completed_trials_per_year}

**Value**: 1,980

Current completed trials per year (trials Ã— completion rate)

$$
Completed_{current} = 3,300 \times 0.60 = 1,980
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#current-capacity](../appendix/research-acceleration-model.qmd#current-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Daily Cost Inefficiency Billions {#sec-daily_cost_inefficiency_billions}

**Value**: $327M

Daily cost of healthcare system inefficiency

**Methodology**: [../solution/dfda.qmd#cost-of-delay](../solution/dfda.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dct Platform Funding Medium Billions {#sec-dct_platform_funding_medium_billions}

**Value**: $500M

Mid-range funding for commercial DCT platform

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#analogous-rom](../appendix/dfda-cost-benefit-analysis.qmd#analogous-rom)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Deaths During Reading Section {#sec-deaths_during_reading_section}

**Value**: 410

Deaths from curable diseases during reading one section

**Methodology**: [../solution/dfda.qmd#cost-of-delay](../solution/dfda.qmd#cost-of-delay)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Death Spending Misallocation Factor {#sec-death_spending_misallocation_factor}

**Value**: 1,750

Misallocation factor for spending on death vs prevention

**Methodology**: [../problem/cost-of-war.qmd#misallocation](../problem/cost-of-war.qmd#misallocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Active Trials {#sec-dfda_active_trials}

**Value**: 200K

Active trials at any given time (3-12 month duration)

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Annual Opex {#sec-dfda_annual_opex}

**Value**: $40M

Total annual dFDA operational costs (sum of all components: $15M + $10M + $8M + $5M + $2M)

$$
OPEX_{total} = \sum_{i=1}^{5} OPEX_i = 0.015 + 0.010 + 0.008 + 0.005 + 0.002
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Avoided Regulatory Delay Cost Annual {#sec-dfda_avoided_regulatory_delay_cost_annual}

**Value**: $11.1T

Annual economic value of regulatory delay costs avoided by dFDA

$$
Value_{avoided} = 74M \times \$150k = \$11.1T
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Avoided Regulatory Delay Dalys Annual {#sec-dfda_avoided_regulatory_delay_dalys_annual}

**Value**: 74M

Annual DALYs saved by dFDA eliminating regulatory efficacy lag

$$
DALY_{avoided} = 77.9M \times 0.95 = 74M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Completed Trials Per Year {#sec-dfda_completed_trials_per_year}

**Value**: 361K

dFDA completed trials per year (capacity Ã— completion rate)

$$
Completed_{dFDA} = 380,000 \times 0.95 = 361,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Drug Approvals Per Year High {#sec-dfda_drug_approvals_per_year_high}

**Value**: 2,000

Optimistic drug approvals estimate (40x current)

$$
Approvals_{high} = 50 \times 40 = 2,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#approval-projections](../appendix/research-acceleration-model.qmd#approval-projections)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Drug Approvals Per Year Low {#sec-dfda_drug_approvals_per_year_low}

**Value**: 1,000

Conservative drug approvals estimate (20x current)

$$
Approvals_{low} = 50 \times 20 = 1,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#approval-projections](../appendix/research-acceleration-model.qmd#approval-projections)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Eligible Patients Global {#sec-dfda_eligible_patients_global}

**Value**: 1.20B

Global eligible patients with minimal exclusions

$$
Eligible_{dFDA} = 2.4B \times 0.50 = 1.2B
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#eligible-population](../appendix/research-acceleration-model.qmd#eligible-population)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Gross Savings Annual {#sec-dfda_gross_savings_annual}

**Value**: $50B

Annual gross savings from 50% trial cost reduction

$$
Savings_{gross} = \$100B \times 0.50 = \$50B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction](../appendix/dfda-cost-benefit-analysis.qmd#cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Icer Per Qaly {#sec-dfda_icer_per_qaly}

**Value**: $-59.5T

dFDA Infrastructure ICER per QALY (net incremental cost Ã· QALYs gained)

$$
\text{ICER} = \frac{\text{Net Incremental Cost (Annual)}}{\text{QALYs Gained (Annual)}} = \frac{-\$49.96\text{B}}{840{,}000 \text{ QALYs}} = -\$59{,}476 \text{ per QALY}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis](../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Large Trial Recruitment Months {#sec-dfda_large_trial_recruitment_months}

**Value**: 3

Months to recruit 10,000+ patients in dFDA system

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-speed](../appendix/research-acceleration-model.qmd#recruitment-speed)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Large Trial Size {#sec-dfda_large_trial_size}

**Value**: 10,000

Large dFDA pragmatic trial size

**Methodology**: [../appendix/research-acceleration-model.qmd#trial-sizes](../appendix/research-acceleration-model.qmd#trial-sizes)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Net Incremental Cost Annual {#sec-dfda_net_incremental_cost_annual}

**Value**: $-50B

Net incremental cost for dFDA (operational costs minus R&D savings)

$$
NetCost = \$0.040B - \$50.0B = -\$49.96B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#net-incremental-cost](../appendix/dfda-cost-benefit-analysis.qmd#net-incremental-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Net Savings Annual {#sec-dfda_net_savings_annual}

**Value**: $50B

Annual net savings (gross savings minus operational costs)

$$
Savings_{net} = \$50B - \$0.04B = \$49.96B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#net-savings](../appendix/dfda-cost-benefit-analysis.qmd#net-savings)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Adoption Ramp Years {#sec-dfda_npv_adoption_ramp_years}

**Value**: 5

Years to reach full dFDA adoption

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#adoption-curve](../appendix/dfda-cost-benefit-analysis.qmd#adoption-curve)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Annual Opex Billions {#sec-dfda_npv_annual_opex_billions}

**Value**: $18.9M

dFDA core platform annual opex (midpoint of $11-26.5M)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Annual Opex Total {#sec-dfda_npv_annual_opex_total}

**Value**: $40M

Total NPV annual opex (dFDA core + DIH initiatives)

$$
C_{op} = \$0.01895B + \$0.02110B = \$0.04005B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Benefit {#sec-dfda_npv_benefit}

**Value**: $249B

NPV of dFDA benefits with 5-year adoption ramp (10-year horizon)

$$
PV_{benefits} = \sum_{t=1}^{10} \frac{NetSavings \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-benefit](../appendix/dfda-cost-benefit-analysis.qmd#npv-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Net Benefit Conservative {#sec-dfda_npv_net_benefit_conservative}

**Value**: $249B

Conservative NPV benefit from dFDA R&D savings (10-year discounted with adoption ramp)

$$
Benefit_{NPV} = \sum_{t=1}^{10} \frac{NetSavings \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-net-benefit](../appendix/dfda-cost-benefit-analysis.qmd#npv-net-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Pv Annual Opex {#sec-dfda_npv_pv_annual_opex}

**Value**: $269M

Present value of annual opex over 10 years (NPV formula)

$$
PV_{opex} = \$0.04005B \times \frac{1 - 1.08^{-10}}{0.08} \approx \$0.269B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-calculation](../appendix/dfda-cost-benefit-analysis.qmd#npv-calculation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Total Cost {#sec-dfda_npv_total_cost}

**Value**: $538M

Total NPV cost (upfront + PV of annual opex)

$$
TotalCost_{NPV} = \$0.26975B + \$0.269B \approx \$0.54B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-total-cost](../appendix/dfda-cost-benefit-analysis.qmd#npv-total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Upfront Cost Billions {#sec-dfda_npv_upfront_cost_billions}

**Value**: $40M

dFDA core platform build cost

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Npv Upfront Cost Total {#sec-dfda_npv_upfront_cost_total}

**Value**: $270M

Total NPV upfront costs (dFDA core + DIH initiatives)

$$
C_0 = \$0.040B + \$0.22975B = \$0.26975B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Opex Community Billions {#sec-dfda_opex_community_billions}

**Value**: $2.00M

dFDA community support costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Opex Infrastructure Billions {#sec-dfda_opex_infrastructure_billions}

**Value**: $8.00M

dFDA infrastructure costs (cloud, security)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Opex Platform Maintenance Billions {#sec-dfda_opex_platform_maintenance_billions}

**Value**: $15M

dFDA platform maintenance costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Opex Regulatory Billions {#sec-dfda_opex_regulatory_billions}

**Value**: $5.00M

dFDA regulatory coordination costs

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Opex Staff Billions {#sec-dfda_opex_staff_billions}

**Value**: $10M

dFDA staff costs (minimal, AI-assisted)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown](../appendix/dfda-cost-benefit-analysis.qmd#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Qalys Monetized {#sec-dfda_qalys_monetized}

**Value**: $126

Monetized value of dFDA QALYs (QALYs Ã— economic value)

$$
Value_{QALY} = 840,000 \times \$150,000 / 10^9 = \$126B
$$

**Methodology**: [../appendix/dfda-qaly-model.qmd#monetized-value](../appendix/dfda-qaly-model.qmd#monetized-value)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Qalys With Regulatory Avoidance Monetized {#sec-dfda_qalys_with_regulatory_avoidance_monetized}

**Value**: $11.1K

Monetized value of comprehensive dFDA benefits including regulatory delay avoidance

$$
Value_{total} = 74.14M \times \$150k / 10^9 = \$11.12T
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Regulatory Delay Avoidance Fraction {#sec-dfda_regulatory_delay_avoidance_fraction}

**Value**: 95%

Fraction of regulatory delay eliminated by dFDA provisional access post-Phase I

$$
Avoidance = 8.2 \div (8.2 + 2.3) \approx 0.78 \text{ (use 0.95 conservatively)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Roi Simple {#sec-dfda_roi_simple}

**Value**: 1,250

Simple ROI without NPV adjustment (gross savings / annual opex)

$$
ROI_{simple} = \frac{\$50B}{\$0.04B} = 1,250:1
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#roi-simple](../appendix/dfda-cost-benefit-analysis.qmd#roi-simple)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Small Trial Recruitment Weeks {#sec-dfda_small_trial_recruitment_weeks}

**Value**: 3

Weeks to recruit 1,000 patients in dFDA system

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-speed](../appendix/research-acceleration-model.qmd#recruitment-speed)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Small Trial Size {#sec-dfda_small_trial_size}

**Value**: 1,000

Typical dFDA trial size

**Methodology**: [../appendix/research-acceleration-model.qmd#trial-sizes](../appendix/research-acceleration-model.qmd#trial-sizes)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Target Cost Per Patient Usd {#sec-dfda_target_cost_per_patient_usd}

**Value**: $1.00K

Target cost per patient in USD (same as DFDA_TARGET_COST_PER_PATIENT but in dollars)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#cost-per-patient](../appendix/dfda-cost-benefit-analysis.qmd#cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Trials Per Year Capacity {#sec-dfda_trials_per_year_capacity}

**Value**: 380K

Maximum trials per year possible with 115x acceleration

$$
Trials_{dFDA} = 3,300 \times 115 = 379,500 \approx 380,000
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#dfda-capacity](../appendix/research-acceleration-model.qmd#dfda-capacity)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Upfront Build Billions {#sec-dfda_upfront_build_billions}

**Value**: $40M

dFDA platform one-time build cost (central estimate)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#build-costs](../appendix/dfda-cost-benefit-analysis.qmd#build-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dfda Upfront Build Max Billions {#sec-dfda_upfront_build_max_billions}

**Value**: $46M

dFDA platform one-time build cost (high estimate)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#build-costs](../appendix/dfda-cost-benefit-analysis.qmd#build-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Diabetes Cure Payment Estimate {#sec-diabetes_cure_payment_estimate}

**Value**: $10K

Estimated one-time payment for diabetes cure

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dih Npv Annual Opex Initiatives Billions {#sec-dih_npv_annual_opex_initiatives_billions}

**Value**: $21.1M

DIH broader initiatives annual opex (medium case)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dih Npv Upfront Cost Initiatives Billions {#sec-dih_npv_upfront_cost_initiatives_billions}

**Value**: $230M

DIH broader initiatives upfront cost (medium case)

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#npv-costs](../appendix/dfda-cost-benefit-analysis.qmd#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dih Treasury Trial Subsidies Max {#sec-dih_treasury_trial_subsidies_max}

**Value**: $20B

Maximum annual clinical trial subsidies from DIH Treasury

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#trial-subsidies](../appendix/dfda-cost-benefit-analysis.qmd#trial-subsidies)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dih Treasury Trial Subsidies Min {#sec-dih_treasury_trial_subsidies_min}

**Value**: $10B

Minimum annual clinical trial subsidies from DIH Treasury

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#trial-subsidies](../appendix/dfda-cost-benefit-analysis.qmd#trial-subsidies)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Disease Related Caregiver Pct {#sec-disease_related_caregiver_pct}

**Value**: 40%

Percentage of caregiving for treatable disease conditions (vs aging, disability, children)

**Methodology**: [Disease-Related Caregiving Analysis](#disease-related-caregiving-estimate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Disease Vs Terrorism Deaths Ratio {#sec-disease_vs_terrorism_deaths_ratio}

**Value**: 18,274

Ratio of annual disease deaths to 9/11 terrorism deaths

*Formula*: `ANNUAL_DISEASE_DEATHS Ã· 911_DEATHS`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Disease Vs War Deaths Ratio {#sec-disease_vs_war_deaths_ratio}

**Value**: 1.63

Ratio of annual disease deaths to war deaths

*Formula*: `ANNUAL_DISEASE_DEATHS Ã· WAR_DEATHS`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Dividend Coverage Factor {#sec-dividend_coverage_factor}

**Value**: 680

Coverage factor of treaty funding vs dFDA opex (sustainability margin)

$$
Coverage = \$27.18B / \$0.04B = 679x
$$

**Methodology**: [../strategy/roadmap.qmd#sustainability](../strategy/roadmap.qmd#sustainability)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Drug Price Reduction Savings High {#sec-drug_price_reduction_savings_high}

**Value**: $180B

High estimate of annual savings from drug price reductions (50% reduction of $360B U.S. spending)

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Drug Price Reduction Savings Low {#sec-drug_price_reduction_savings_low}

**Value**: $72B

Low estimate of annual savings from drug price reductions (20% reduction of $360B U.S. spending)

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate {#sec-effective_hourly_rate}

**Value**: $292B

Effective hourly rate from treaty participation

$$
HourlyRate = \frac{\$4,300,000}{14.75} \approx \$291,525/hr
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate Lifetime Benefit {#sec-effective_hourly_rate_lifetime_benefit}

**Value**: $4.30T

Lifetime benefit in USD (not millions)

$$
Benefit = \$4.3M \times 10^6 = \$4,300,000
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate Lifetime Benefit Millions {#sec-effective_hourly_rate_lifetime_benefit_millions}

**Value**: $4.30M

Lifetime benefit for age 30 baseline scenario

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate Vs Ceo Multiplier {#sec-effective_hourly_rate_vs_ceo_multiplier}

**Value**: 29.2M

Effective rate multiplier vs CEO rate

$$
Multiplier = \frac{\$291,525}{\$10,000} \approx 29x
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Effective Hourly Rate Vs Wage Multiplier {#sec-effective_hourly_rate_vs_wage_multiplier}

**Value**: 9.74B

Effective rate multiplier vs average US wage

$$
Multiplier = \frac{\$291,525}{\$30} \approx 9,718x
$$

**Methodology**: [../solution/wishocracy.qmd#effective-hourly-rate](../solution/wishocracy.qmd#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected Roi Conservative Dfda {#sec-expected_roi_conservative_dfda}

**Value**: 46.3

Expected ROI for dFDA accounting for 10% political success probability

$$
E[ROI]_{\text{conservative}} = 463 \times 0.10 = 46.3
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected Roi Moderate Dfda {#sec-expected_roi_moderate_dfda}

**Value**: 116

Expected ROI for dFDA accounting for 25% political success probability

$$
E[ROI]_{\text{moderate}} = 463 \times 0.25 = 115.8
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Expected Roi Optimistic Dfda {#sec-expected_roi_optimistic_dfda}

**Value**: 232

Expected ROI for dFDA accounting for 50% political success probability

$$
E[ROI]_{\text{optimistic}} = 463 \times 0.50 = 231.5
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Family Office Investment Min Millions {#sec-family_office_investment_min_millions}

**Value**: $5.00M

Minimum investment for family offices

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding Base Case {#sec-foundation_funding_base_case}

**Value**: $442M

Nonprofit foundation funding in base case scenario (health R&D, civic infrastructure)

$$
Foundation_{base} = \$940M \times 47\% = \$442M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding Percentage {#sec-foundation_funding_percentage}

**Value**: 51%

Foundation funding as percentage of total campaign cost (realistic scenario)

$$
Foundation\% = \frac{\$519M}{\$1,020M} = 51\%
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding Realistic {#sec-foundation_funding_realistic}

**Value**: $519M

Nonprofit foundation funding in realistic scenario (health R&D, civic infrastructure)

$$
Foundation_{realistic} = \$1,020M \times 51\% = \$519M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Funding Worst Case {#sec-foundation_funding_worst_case}

**Value**: $542M

Nonprofit foundation funding in worst-case scenario (health R&D, civic infrastructure)

$$
Foundation_{worst} = \$1,206M \times 45\% = \$542M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Legal Compliance Realistic {#sec-foundation_legal_compliance_realistic}

**Value**: $53M

Foundation funding for legal/compliance (international health law research)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Lobbying Realistic {#sec-foundation_lobbying_realistic}

**Value**: $0

Foundation funding for political lobbying (zero due to 501c3 restrictions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Operations Realistic {#sec-foundation_operations_realistic}

**Value**: $20M

Foundation funding for operations (nonprofit R&D staff)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Partnerships Realistic {#sec-foundation_partnerships_realistic}

**Value**: $29M

Foundation funding for partnerships (NGOs, patient advocacy, scientific institutions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Reserve Realistic {#sec-foundation_reserve_realistic}

**Value**: $37M

Foundation funding for reserve (nonprofit contingency)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Tech Rd Realistic {#sec-foundation_tech_rd_realistic}

**Value**: $226M

Foundation funding for technology R&D (dFDA platform, Wishocracy, infrastructure)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Foundation Viral Referendum Realistic {#sec-foundation_viral_referendum_realistic}

**Value**: $77M

Foundation funding for viral referendum platform (biometric verification, civic infrastructure)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Conflict Deaths Total {#sec-global_annual_conflict_deaths_total}

**Value**: 245K

Total annual conflict deaths globally (sum of combat, terror, state violence)

$$
Deaths_{total} = 233,600 + 8,300 + 2,700 = 244,600
$$

**Methodology**: [../problem/cost-of-war.qmd#death-accounting](../problem/cost-of-war.qmd#death-accounting)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Deaths Curable Diseases {#sec-global_annual_deaths_curable_diseases}

**Value**: 54.8M

Annual deaths from curable diseases globally

*Formula*: `GLOBAL_DAILY_DEATHS_CURABLE_DISEASES Ã— 365`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Human Cost Active Combat {#sec-global_annual_human_cost_active_combat}

**Value**: $2.34K

Annual cost of combat deaths (deaths Ã— VSL)

$$
Cost_{combat} = 233,600 \times \$10M / 10^9 = \$2,336B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Human Cost State Violence {#sec-global_annual_human_cost_state_violence}

**Value**: $27

Annual cost of state violence deaths (deaths Ã— VSL)

$$
Cost_{state} = 2,700 \times \$10M / 10^9 = \$27B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Human Cost Terror Attacks {#sec-global_annual_human_cost_terror_attacks}

**Value**: $83

Annual cost of terror deaths (deaths Ã— VSL)

$$
Cost_{terror} = 8,300 \times \$10M / 10^9 = \$83B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Human Life Losses Conflict {#sec-global_annual_human_life_losses_conflict}

**Value**: $2.45K

Total annual human life losses from conflict (sum of combat, terror, state violence)

$$
Cost_{human} = \$2,336B + \$83B + \$27B = \$2,446B
$$

**Methodology**: [../problem/cost-of-war.qmd#human-cost](../problem/cost-of-war.qmd#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Infrastructure Destruction Conflict {#sec-global_annual_infrastructure_destruction_conflict}

**Value**: $1.88T

Total annual infrastructure destruction (sum of transportation, energy, communications, water, education, healthcare)

$$
Infra_{damage} = \$487.3B + \$421.7B + \$298.1B + \$267.8B + \$234.5B + \$165.6B = \$1,875B
$$

**Methodology**: [../problem/cost-of-war.qmd#infrastructure-damage](../problem/cost-of-war.qmd#infrastructure-damage)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual Trade Disruption Conflict {#sec-global_annual_trade_disruption_conflict}

**Value**: $616B

Total annual trade disruption (sum of shipping, supply chain, energy prices, currency instability)

$$
Trade_{disruption} = \$247.1B + \$186.8B + \$124.7B + \$57.4B = \$616B
$$

**Methodology**: [../problem/cost-of-war.qmd#trade-disruption](../problem/cost-of-war.qmd#trade-disruption)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual War Direct Costs Total {#sec-global_annual_war_direct_costs_total}

**Value**: $5.21T

Total annual direct war costs (military spending + infrastructure + human life + trade disruption)

$$
DirectCosts = \$2,718B + \$1,875B + \$2,446B + \$616B = \$7,655B
$$

**Methodology**: [../problem/cost-of-war.qmd#direct-costs](../problem/cost-of-war.qmd#direct-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual War Indirect Costs Total {#sec-global_annual_war_indirect_costs_total}

**Value**: $3.70T

Total annual indirect war costs (opportunity cost + veterans + refugees + environment + mental health + lost productivity)

$$
IndirectCosts = \$2,718B + \$200.1B + \$150B + \$100B + \$232B + \$300B = \$3,700.1B
$$

**Methodology**: [../problem/cost-of-war.qmd#indirect-costs](../problem/cost-of-war.qmd#indirect-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Annual War Total Cost {#sec-global_annual_war_total_cost}

**Value**: $8.91T

Total annual cost of war worldwide (direct + indirect costs)

$$
TotalWarCost = \$7,655B + \$3,700.1B = \$11,355.1B
$$

**Methodology**: [../problem/cost-of-war.qmd#total-cost](../problem/cost-of-war.qmd#total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Cost Per Conflict Death Millions {#sec-global_cost_per_conflict_death_millions}

**Value**: $36.4B

Cost per conflict death (war cost Ã· deaths)

$$
CostPerDeath = \frac{\$11,355.1B \times 10^9}{244,600} / 10^6 \approx \$46.4M
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Cost Per Life Saved Med Research Annual {#sec-global_cost_per_life_saved_med_research_annual}

**Value**: $16.1T

Cost per life saved by medical research

$$
CostPerLifeSaved = \frac{\$67.5B \times 10^9}{4,200,000} \approx \$16,071
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Dfda Qalys Gained Annual {#sec-global_dfda_qalys_gained_annual}

**Value**: 840K

Annual QALYs gained from dFDA

**Methodology**: [../appendix/dfda-qaly-model.qmd](../appendix/dfda-qaly-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Dfda Qalys With Regulatory Avoidance {#sec-global_dfda_qalys_with_regulatory_avoidance}

**Value**: 74.1M

Total annual QALYs from dFDA including regulatory delay avoidance (top-down comprehensive estimate)

$$
QALYs_{total} = 74M + 140k \approx 74.14M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance](../appendix/dfda-cost-benefit-analysis.qmd#regulatory-delay-avoidance)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Military Spending Per Capita Annual {#sec-global_military_spending_per_capita_annual}

**Value**: $340

Per capita military spending globally

$$
PerCapita_{military} = \$2,718B / 8.0B = \$339.75
$$

**Methodology**: [../problem/cost-of-war.qmd#per-capita](../problem/cost-of-war.qmd#per-capita)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Military Spending Post Treaty Annual 2024 {#sec-global_military_spending_post_treaty_annual_2024}

**Value**: $2.69T

Global military spending after 1% treaty reduction

$$
PostTreaty_{military} = \$2,718B \times 0.99 = \$2,690.82B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#post-treaty](../strategy/treaty-adoption-strategy.qmd#post-treaty)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Total Health And War Cost Annual {#sec-global_total_health_and_war_cost_annual}

**Value**: $126T

Total annual cost of war and disease with all externalities (direct + indirect costs for both)

*Formula*: `WAR_TOTAL_COSTS + SYMPTOMATIC_TREATMENT + DISEASE_BURDEN`

**Methodology**: [../appendix/humanity-budget-overview.qmd](../appendix/humanity-budget-overview.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global Total War Cost Per Capita Annual {#sec-global_total_war_cost_per_capita_annual}

**Value**: $1.11K

Per capita total war cost globally

$$
PerCapita_{war} = \$11,355.1B / 8.0B = \$1,419.39
$$

**Methodology**: [../problem/cost-of-war.qmd#per-capita](../problem/cost-of-war.qmd#per-capita)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Global War Direct Cost Per Second {#sec-global_war_direct_cost_per_second}

**Value**: $165T

Direct war cost per second globally

$$
CostPerSecond = \frac{\$7,655B \times 10^9}{31,557,600} \approx \$242,749
$$

**Methodology**: [../problem/cost-of-war.qmd#cost-per-second](../problem/cost-of-war.qmd#cost-per-second)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## High Net Worth Investor Min Millions {#sec-high_net_worth_investor_min_millions}

**Value**: $1.00M

Minimum investment for high net worth individuals

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Icer Investor Funded {#sec-icer_investor_funded}

**Value**: $-187K

ICER for investor-funded scenario (VICTORY Social Impact Bonds)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Icer Opportunity Cost {#sec-icer_opportunity_cost}

**Value**: $-157K

ICER counting redirected military spending as opportunity cost

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer](../appendix/1-percent-treaty-cost-effectiveness.qmd#alternative-icer)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Icer Per Qaly {#sec-icer_per_qaly}

**Value**: $-150T

Incremental Cost-Effectiveness Ratio (ICER) per QALY gained

*Formula*: `(TREATY_TOTAL_ANNUAL_COSTS - TREATY_TOTAL_ANNUAL_BENEFITS) Ã— 1B Ã· TREATY_TOTAL_QALYS_GAINED_ANNUAL`

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#icer-calculation](../appendix/1-percent-treaty-cost-effectiveness.qmd#icer-calculation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Institutional Investor Min Millions {#sec-institutional_investor_min_millions}

**Value**: $10M

Minimum investment for institutional investors

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lifetime War Cost Per Capita {#sec-lifetime_war_cost_per_capita}

**Value**: $89.1K

Lifetime war cost per person (80-year lifespan)

$$
Lifetime_{war} = \$1,419.39 \times 80 = \$113,551
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd#lifetime-cost](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd#lifetime-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lobbyist Bond Investment Max Millions {#sec-lobbyist_bond_investment_max_millions}

**Value**: $20M

Maximum bond investment for lobbyist incentives

**Methodology**: [../strategy/roadmap.qmd#lobbyist-incentives](../strategy/roadmap.qmd#lobbyist-incentives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Lobbyist Bond Investment Min Millions {#sec-lobbyist_bond_investment_min_millions}

**Value**: $5.00M

Minimum bond investment for lobbyist incentives

**Methodology**: [../strategy/roadmap.qmd#lobbyist-incentives](../strategy/roadmap.qmd#lobbyist-incentives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Longevity Therapy Savings 30Yr {#sec-longevity_therapy_savings_30yr}

**Value**: $150K

30-year savings from longevity therapy per person

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Medical Research Pct Of Disease Burden {#sec-medical_research_pct_of_disease_burden}

**Value**: 0.0535%

Medical research spending as percentage of total disease burden

*Formula*: `MED_RESEARCH Ã· TOTAL_BURDEN`

**Methodology**: [../economics/economics.qmd](../economics/economics.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Military Vs Medical Research Ratio {#sec-military_vs_medical_research_ratio}

**Value**: 40.3

Ratio of military spending to medical research spending

$$
Ratio = \frac{\$2,718B}{\$67.5B} \approx 40.3:1
$$

**Methodology**: [../problem/cost-of-war.qmd#misallocation](../problem/cost-of-war.qmd#misallocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Misallocation Factor Death Vs Saving {#sec-misallocation_factor_death_vs_saving}

**Value**: 2,266

Misallocation factor: cost to kill vs cost to save

$$
Misallocation = \frac{\$46.4M}{\$16,071} \approx 2,889x
$$

**Methodology**: [../problem/cost-of-war.qmd#grotesque-mathematics](../problem/cost-of-war.qmd#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Multiplier Vs Givewell {#sec-multiplier_vs_givewell}

**Value**: 1166326B

Cost-effectiveness multiplier vs GiveWell top charities

$$
Multiplier = \frac{|-\$6.19M \times 10^9|}{\$4,500} \approx 1,376x
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#givewell-comparison](../appendix/1-percent-treaty-cost-effectiveness.qmd#givewell-comparison)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Net Benefit Per Life Saved {#sec-net_benefit_per_life_saved}

**Value**: $-5.25B

Net benefit per life saved (ICER Ã— QALYs/life)

$$
BenefitPerLife = -\$59,476 Ã· 1M \times 35 = -\$2.08M
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#cost-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#cost-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Opportunity Cost Per Day {#sec-opportunity_cost_per_day}

**Value**: $3.39B

Foregone economic value per day from not implementing system

*Formula*: `TREATY_COMPLETE_CASE_ANNUAL_BENEFITS Ã· 365`

**Methodology**: [../economics/economics.qmd#the-opportunity-cost-clock](../economics/economics.qmd#the-opportunity-cost-clock)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Opportunity Cost Per Second {#sec-opportunity_cost_per_second}

**Value**: $39.3T

Foregone economic value per second from not implementing system

*Formula*: `TREATY_COMPLETE_CASE_ANNUAL_BENEFITS Ã— 1B Ã· SECONDS_PER_YEAR`

**Methodology**: [../economics/economics.qmd#the-opportunity-cost-clock](../economics/economics.qmd#the-opportunity-cost-clock)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Optimistic Scenario Roi {#sec-optimistic_scenario_roi}

**Value**: 1,281

Optimistic scenario ROI (net benefit Ã· total costs)

$$
ROI_{optimistic} = \$294.8B / \$0.230B = 1,282:1
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Partial Success Bondholder Payout {#sec-partial_success_bondholder_payout}

**Value**: $1.36B

Bondholder payout in partial success scenario

$$
Payout_{partial} = \$13.59B \times 0.10 = \$1.36B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Partial Success Dih Revenue {#sec-partial_success_dih_revenue}

**Value**: $13.6B

DIH revenue in partial success scenario

$$
Revenue_{partial} = \$2,718B \times 0.50 \times 0.01 = \$13.59B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Partial Success Investor Roi {#sec-partial_success_investor_roi}

**Value**: 136%

Investor ROI in partial success scenario

$$
ROI_{partial} = \$1.36B / \$1B = 1.359 = 135.9\%
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Partial Success Military Spending Share {#sec-partial_success_military_spending_share}

**Value**: 50%

Military spending share for partial success scenario (US, EU, UK)

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Partial Success Research Funding {#sec-partial_success_research_funding}

**Value**: $12.2B

Research funding in partial success scenario

$$
Research_{partial} = \$13.59B \times 0.90 = \$12.23B
$$

**Methodology**: [../strategy/treaty-adoption-strategy.qmd#partial-success](../strategy/treaty-adoption-strategy.qmd#partial-success)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Patient Cure Copay Max {#sec-patient_cure_copay_max}

**Value**: $1.00K

Maximum patient copay for cure

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Annual Societal Benefit {#sec-peace_dividend_annual_societal_benefit}

**Value**: $89.1B

Annual peace dividend from 1% reduction in total war costs

$$
Peace\_Dividend = \$11,355B \times 0.01 = \$113.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-dividend](../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Conflict Reduction {#sec-peace_dividend_conflict_reduction}

**Value**: $61.9B

Conflict reduction benefits from 1% less military spending (lower confidence - assumes proportional relationship)

$$
PD_{conflict} = \$113.55B - \$27.18B = \$86.37B
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Direct Costs {#sec-peace_dividend_direct_costs}

**Value**: $52.1B

Annual savings from 1% reduction in direct war costs

$$
PD_{direct} = \$7,655B \times 0.01 = \$76.55B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Direct Fiscal Savings {#sec-peace_dividend_direct_fiscal_savings}

**Value**: $27.2B

Direct fiscal savings from 1% military spending reduction (high confidence)

$$
PD_{fiscal} = \$27.18B
$$

**Methodology**: [SIPRI Military Spending Database](#sipri-2024-spending)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Environmental {#sec-peace_dividend_environmental}

**Value**: $1.00B

Annual savings from 1% reduction in environmental damage

$$
PD_{env} = \$10B \times 0.01 = \$0.10B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Human Casualties {#sec-peace_dividend_human_casualties}

**Value**: $24

Annual savings from 1% reduction in human casualties

$$
PD_{human} = \$2,446B \times 0.01 = \$24.46B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Indirect Costs {#sec-peace_dividend_indirect_costs}

**Value**: $37B

Annual savings from 1% reduction in indirect war costs

$$
PD_{indirect} = \$3,700.1B \times 0.01 = \$37.00B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Infrastructure {#sec-peace_dividend_infrastructure}

**Value**: $18.8B

Annual savings from 1% reduction in infrastructure destruction

$$
PD_{infra} = \$1,875B \times 0.01 = \$18.75B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Lost Economic Growth {#sec-peace_dividend_lost_economic_growth}

**Value**: $27.2B

Annual savings from 1% reduction in lost economic growth

$$
PD_{growth} = \$2,718B \times 0.01 = \$27.18B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Lost Human Capital {#sec-peace_dividend_lost_human_capital}

**Value**: $3.00B

Annual savings from 1% reduction in lost human capital

$$
PD_{capital} = \$30B \times 0.01 = \$0.30B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Ptsd {#sec-peace_dividend_ptsd}

**Value**: $2.32B

Annual savings from 1% reduction in PTSD and mental health costs

$$
PD_{PTSD} = \$23.2B \times 0.01 = \$0.23B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Refugee Support {#sec-peace_dividend_refugee_support}

**Value**: $1.50B

Annual savings from 1% reduction in refugee support costs

$$
PD_{refugee} = \$15B \times 0.01 = \$0.15B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Roi {#sec-peace_dividend_roi}

**Value**: 4.28

Total benefit per dollar redirected (savings + funding captured)

$$
ROI_{peace} = \frac{\$113.55B + \$27.18B}{\$27.18B} = 5.18
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Trade Disruption {#sec-peace_dividend_trade_disruption}

**Value**: $6.16B

Annual savings from 1% reduction in trade disruption

$$
PD_{trade} = \$616B \times 0.01 = \$6.16B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Peace Dividend Veteran Healthcare {#sec-peace_dividend_veteran_healthcare}

**Value**: $2.00B

Annual savings from 1% reduction in veteran healthcare costs

$$
PD_{veteran} = \$20.01B \times 0.01 = \$0.20B
$$

**Methodology**: [../economics/peace-dividend.qmd](../economics/peace-dividend.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Pharma Cure Payment Per Patient {#sec-pharma_cure_payment_per_patient}

**Value**: $90K

Pharma payment per cured patient in 50/50 model

**Methodology**: [../economics/health-savings-sharing-model.qmd](../economics/health-savings-sharing-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Profit Per Life Saved {#sec-profit_per_life_saved}

**Value**: $168K

System profit per life saved (specific calculation)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Faster Access {#sec-qalys_from_faster_access}

**Value**: 200K

Base case QALYs from faster drug access

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Faster Access Conservative {#sec-qalys_from_faster_access_conservative}

**Value**: 90,000

Conservative QALYs from faster access (15 drugs/yr Ã— 1 yr accel Ã— 6k QALYs/drug)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Faster Access Optimistic {#sec-qalys_from_faster_access_optimistic}

**Value**: 500K

Optimistic QALYs from faster drug access

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From New Therapies {#sec-qalys_from_new_therapies}

**Value**: 500K

Base case QALYs from enabling new therapies for rare/untreatable diseases

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From New Therapies Conservative {#sec-qalys_from_new_therapies_conservative}

**Value**: 50,000

Conservative QALYs from new therapies (5 therapies/yr Ã— 2k patients Ã— 5 QALYs/patient)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From New Therapies Optimistic {#sec-qalys_from_new_therapies_optimistic}

**Value**: 3.00M

Optimistic QALYs from new therapies

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Prevention {#sec-qalys_from_prevention}

**Value**: 140K

Base case QALYs from better prevention through real-world data

**Methodology**: [../appendix/dfda-qaly-model.qmd#base-case](../appendix/dfda-qaly-model.qmd#base-case)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Prevention Conservative {#sec-qalys_from_prevention_conservative}

**Value**: 50,000

Conservative QALYs from prevention (5M patients Ã— 0.01 QALYs/patient)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys From Prevention Optimistic {#sec-qalys_from_prevention_optimistic}

**Value**: 150K

Optimistic QALYs from prevention

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys Total Conservative {#sec-qalys_total_conservative}

**Value**: 190K

Total conservative QALYs (90k + 50k + 50k)

**Methodology**: [../appendix/dfda-qaly-model.qmd#conservative-scenario](../appendix/dfda-qaly-model.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qalys Total Optimistic {#sec-qalys_total_optimistic}

**Value**: 3.65M

Total optimistic QALYs (500k + 150k + 3M)

**Methodology**: [../appendix/dfda-qaly-model.qmd#optimistic-scenario](../appendix/dfda-qaly-model.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Qualified Investor Min Thousands {#sec-qualified_investor_min_thousands}

**Value**: $100K

Minimum investment for qualified investors

**Methodology**: [../economics/victory-bonds.qmd](../economics/victory-bonds.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Recruitment Speed Multiplier {#sec-recruitment_speed_multiplier}

**Value**: 25

Recruitment speed multiplier (25x faster from 2% â†’ 50% eligibility)

$$
Recruitment_{mult} = \frac{0.50}{0.002} = 25
$$

**Methodology**: [../appendix/research-acceleration-model.qmd#recruitment-acceleration](../appendix/research-acceleration-model.qmd#recruitment-acceleration)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Refugee Lost Productivity Global Total {#sec-refugee_lost_productivity_global_total}

**Value**: $2.54K

Total global lost refugee productivity

$$
RefugeeLosses = \frac{108.4M \times \$23,400}{10^9} = \$2,536.6B
$$

**Methodology**: [../problem/cost-of-war.qmd#refugee-costs](../problem/cost-of-war.qmd#refugee-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Annual Dalys {#sec-regulatory_delay_annual_dalys}

**Value**: 77.9M

Annual DALYs lost to regulatory delay under current system

$$
DALY_{annual} = 4.83B \div 62 = 77.9M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Annual Loss {#sec-regulatory_delay_annual_loss}

**Value**: $11.7T

Annualized economic loss from regulatory delay

$$
Annual_{loss} = 77.9M \times \$150k = \$11.685T/year
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Dalys Billions {#sec-regulatory_delay_dalys_billions}

**Value**: 4.83

Total Disability-Adjusted Life Years lost to regulatory delay (1962-2024)

$$
DALY_{total} = YLL + YLD = 3.14B + 1.69B = 4.83B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Deaths Lower Bound Millions {#sec-regulatory_delay_deaths_lower_bound_millions}

**Value**: 110

Lower bound excess deaths from regulatory delay (1962-2024, steel-man scenario)

$$
D_{total}^{lower} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence â€¢ âš–ï¸ Conservative estimate*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Deaths Mean Millions {#sec-regulatory_delay_deaths_mean_millions}

**Value**: 185

Mean estimate excess deaths from regulatory delay (1962-2024)

$$
D_{total}^{mean} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Deaths Upper Bound Millions {#sec-regulatory_delay_deaths_upper_bound_millions}

**Value**: 318

Upper bound excess deaths from regulatory delay (1962-2024, linear innovation trajectory)

$$
D_{total}^{upper} = D_{lag} + D_{void}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#mortality-estimates](../appendix/regulatory-mortality-analysis.qmd#mortality-estimates)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Economic Loss {#sec-regulatory_delay_economic_loss}

**Value**: $724T

Cumulative economic deadweight loss from regulatory delay (1962-2024, 2024 USD)

$$
DWL = 4.83B \times \$150k = \$724.5T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#economic-valuation](../appendix/regulatory-mortality-analysis.qmd#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Yld Billions {#sec-regulatory_delay_yld_billions}

**Value**: 1.69

Years Lived with Disability during regulatory delay

$$
YLD = 184.6M \times 6 \times 0.35 = 1.69B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Regulatory Delay Yll Billions {#sec-regulatory_delay_yll_billions}

**Value**: 3.14

Years of Life Lost from regulatory delay deaths

$$
YLL = 184.6M \times (79 - 62) = 3.14B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#daly-calculation](../appendix/regulatory-mortality-analysis.qmd#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Research Acceleration Multiplier {#sec-research_acceleration_multiplier}

**Value**: 115

Total research capacity multiplier from dFDA

$$
Multiplier = 1.40 \times 82 = 115
$$

**Methodology**: [../appendix/research-acceleration-model.qmd](../appendix/research-acceleration-model.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi All Direct Benefits {#sec-roi_all_direct_benefits}

**Value**: 1,239

ROI from all direct benefits (peace dividend + dFDA + health gains)

$$
ROI_{complete} = \frac{\$1,238.6B}{\$1.0B} \approx 1,239
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd](../appendix/1-percent-treaty-cost-effectiveness.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi Dfda Savings Only {#sec-roi_dfda_savings_only}

**Value**: 463

ROI from dFDA R&D savings (10-year NPV)

$$
ROI_{NPV} = \frac{\$249.3B}{\$0.54B} \approx 463
$$

**Methodology**: [../figures/dfda-roi-analysis.qmd](../figures/dfda-roi-analysis.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi Discount 1Pct {#sec-roi_discount_1pct}

**Value**: 532

ROI at 1% discount rate (approximate 15% increase from 3% baseline)

$$
ROI_{1\%} \approx 463 \times 1.15 = 532
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi Discount 3Pct {#sec-roi_discount_3pct}

**Value**: 463

ROI at 3% discount rate (baseline)

$$
ROI_{3\%} = 463
$$

**Methodology**: [Direct Calculation](#calculated)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi Discount 5Pct {#sec-roi_discount_5pct}

**Value**: 407

ROI at 5% discount rate (approximate 12% decrease from 3% baseline)

$$
ROI_{5\%} \approx 463 \times 0.88 = 407
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Roi Discount 7Pct {#sec-roi_discount_7pct}

**Value**: 361

ROI at 7% discount rate (approximate 22% decrease from 3% baseline)

$$
ROI_{7\%} \approx 463 \times 0.78 = 361
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Campaign Cost Conservative Billions {#sec-sensitivity_campaign_cost_conservative_billions}

**Value**: $333M

Conservative campaign cost (3-year amortization)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Campaign Cost Optimistic Billions {#sec-sensitivity_campaign_cost_optimistic_billions}

**Value**: $200M

Optimistic campaign cost (5-year amortization)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Cost Per Life Central {#sec-sensitivity_cost_per_life_central}

**Value**: $-7

Central cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Cost Per Life Conservative {#sec-sensitivity_cost_per_life_conservative}

**Value**: $-6

Conservative cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Cost Per Life Optimistic {#sec-sensitivity_cost_per_life_optimistic}

**Value**: $-5

Optimistic cost per life saved

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Dfda Opex Conservative Billions {#sec-sensitivity_dfda_opex_conservative_billions}

**Value**: $60M

Conservative dFDA operational costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Dfda Opex Optimistic Billions {#sec-sensitivity_dfda_opex_optimistic_billions}

**Value**: $30M

Optimistic dFDA operational costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Dfda Savings Conservative {#sec-sensitivity_dfda_savings_conservative}

**Value**: $25B

Conservative dFDA savings estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Dfda Savings Optimistic {#sec-sensitivity_dfda_savings_optimistic}

**Value**: $95B

Optimistic dFDA savings estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Icer Central {#sec-sensitivity_icer_central}

**Value**: $-187K

Central ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Icer Conservative {#sec-sensitivity_icer_conservative}

**Value**: $-171K

Conservative ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Icer Optimistic {#sec-sensitivity_icer_optimistic}

**Value**: $-137K

Optimistic ICER from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Lives Saved Central {#sec-sensitivity_lives_saved_central}

**Value**: 26,446

Central scenario lives saved (total QALYs Ã· QALYs/life)

$$
Lives_{central} = 925,610 / 35 \approx 26,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#central-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Net Benefit Conservative {#sec-sensitivity_net_benefit_conservative}

**Value**: $74.6B

Conservative net benefit from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Net Benefit Optimistic {#sec-sensitivity_net_benefit_optimistic}

**Value**: $295B

Optimistic net benefit from sensitivity analysis

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Peace Dividend Conservative {#sec-sensitivity_peace_dividend_conservative}

**Value**: $50B

Conservative peace dividend estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Peace Dividend Optimistic {#sec-sensitivity_peace_dividend_optimistic}

**Value**: $200B

Optimistic peace dividend estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Peace Qalys Conservative {#sec-sensitivity_peace_qalys_conservative}

**Value**: 17,500

Conservative peace QALYs (500 lives Ã— 35 QALYs/life)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Peace Qalys Optimistic {#sec-sensitivity_peace_qalys_optimistic}

**Value**: 52,500

Optimistic peace QALYs (1,500 lives Ã— 35 QALYs/life)

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Benefits Conservative {#sec-sensitivity_total_benefits_conservative}

**Value**: $75B

Conservative total benefits estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Benefits Optimistic {#sec-sensitivity_total_benefits_optimistic}

**Value**: $295B

Optimistic total benefits estimate

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Costs Conservative Billions {#sec-sensitivity_total_costs_conservative_billions}

**Value**: $393M

Conservative total costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Costs Optimistic Billions {#sec-sensitivity_total_costs_optimistic_billions}

**Value**: $230M

Optimistic total costs

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Qalys Conservative {#sec-sensitivity_total_qalys_conservative}

**Value**: 208K

Conservative total QALYs (peace + dFDA)

$$
QALYs_{conservative} = 17,500 + 190,000 = 207,500
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#conservative-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Sensitivity Total Qalys Optimistic {#sec-sensitivity_total_qalys_optimistic}

**Value**: 3.70M

Optimistic total QALYs (peace + dFDA)

$$
QALYs_{optimistic} = 52,500 + 3,650,000 = 3,702,500
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario](../appendix/1-percent-treaty-cost-effectiveness.qmd#optimistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Simultaneous Trials Multiplier {#sec-simultaneous_trials_multiplier}

**Value**: 20

Simultaneous trials multiplier (20x more trials)

**Methodology**: [../appendix/research-acceleration-model.qmd#capacity-multiplier](../appendix/research-acceleration-model.qmd#capacity-multiplier)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Social Media Participant Target Max {#sec-social_media_participant_target_max}

**Value**: 2,000

Maximum target participant count for social media campaigns

**Methodology**: [../strategy/viral-marketing.qmd](../strategy/viral-marketing.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Social Media Participant Target Min {#sec-social_media_participant_target_min}

**Value**: 500

Minimum target participant count for social media campaigns

**Methodology**: [../strategy/viral-marketing.qmd](../strategy/viral-marketing.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## System Profit Per Life Saved Millions {#sec-system_profit_per_life_saved_millions}

**Value**: $5.87M

System profit per life saved in millions

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life](../appendix/1-percent-treaty-cost-effectiveness.qmd#profit-per-life)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Book Words {#sec-total_book_words}

**Value**: 171K

Total words in the book

**Methodology**: [Book Word Count Analysis](#book-word-count)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Complete Benefits Annual {#sec-total_complete_benefits_annual}

**Value**: $1.21T

Total annual benefits from all 8 benefit categories

$$
TotalBenefits = \$113.55 + \$50 + \$300 + \$100 + \$400 + \$100 + \$100 + \$75 = \$1,238.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#complete-benefits](../appendix/1-percent-treaty-cost-effectiveness.qmd#complete-benefits)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total Time Investment Hours {#sec-total_time_investment_hours}

**Value**: 14.7

Total time investment (reading + actions)

$$
TotalInvestment = 14.3 + 0.45 = 14.75 \text{ hours}
$$

**Methodology**: [../solution/wishocracy.qmd#time-investment](../solution/wishocracy.qmd#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Total War Cost To Who Budget Ratio {#sec-total_war_cost_to_who_budget_ratio}

**Value**: 168

Ratio of total war cost to WHO budget (168x)

**Methodology**: [../problem/cost-of-war.qmd](../problem/cost-of-war.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treatment Acceleration Years Target {#sec-treatment_acceleration_years_target}

**Value**: 2

Target years to market with dFDA

**Methodology**: [../appendix/research-acceleration-model.qmd#target-timeline](../appendix/research-acceleration-model.qmd#target-timeline)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Benefit Multiplier Vs Vaccines {#sec-treaty_benefit_multiplier_vs_vaccines}

**Value**: 9.27

Treaty system benefit multiplier vs childhood vaccination programs

*Formula*: `TREATY_CONSERVATIVE_BENEFIT Ã· CHILDHOOD_VACCINATION_BENEFIT`

**Methodology**: [../economics/economics.qmd#better-than-the-best-charities](../economics/economics.qmd#better-than-the-best-charities)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Annual Cost Amortized {#sec-treaty_campaign_annual_cost_amortized}

**Value**: $250M

Amortized annual campaign cost (total cost Ã· campaign duration)

$$
AnnualCost = \$1B / 4 = \$0.25B
$$

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Budget Lobbying {#sec-treaty_campaign_budget_lobbying}

**Value**: $650M

Political lobbying campaign: direct lobbying (US/EU/G20), Super PACs, opposition research, staff, legal/compliance (exceeds pharma $300M + MIC $150M)

**Methodology**: [../appendix/fundraising-strategy.qmd#campaign-budget-breakdown](../appendix/fundraising-strategy.qmd#campaign-budget-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Budget Mass Bribery Billions {#sec-treaty_campaign_budget_mass_bribery_billions}

**Value**: $140M

Campaign budget for mass mobilization (voting bloc build)

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Budget Referendum {#sec-treaty_campaign_budget_referendum}

**Value**: $300M

Global referendum campaign (get 208M votes): ads, media, partnerships, staff, legal/compliance

**Methodology**: [../appendix/fundraising-strategy.qmd#campaign-budget-breakdown](../appendix/fundraising-strategy.qmd#campaign-budget-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Budget Reserve {#sec-treaty_campaign_budget_reserve}

**Value**: $50M

Reserve fund / contingency buffer

**Methodology**: [../appendix/fundraising-strategy.qmd#campaign-budget-breakdown](../appendix/fundraising-strategy.qmd#campaign-budget-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Budget Super Pacs Billions {#sec-treaty_campaign_budget_super_pacs_billions}

**Value**: $800M

Campaign budget for Super PACs and political lobbying

**Methodology**: [../strategy/roadmap.qmd#campaign-budget](../strategy/roadmap.qmd#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Cost Per Verified Vote Realistic Usd {#sec-treaty_campaign_cost_per_verified_vote_realistic_usd}

**Value**: $1

Realistic all-in cost per verified vote (referral payment + verification cost + overhead)

*Formula*: `REFERRAL_PAYMENT + VERIFICATION_COST + OVERHEAD`

**Methodology**: [../economics/campaign-budget.qmd#verification-cost-analysis](../economics/campaign-budget.qmd#verification-cost-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Cost Per Vote Max Usd {#sec-treaty_campaign_cost_per_vote_max_usd}

**Value**: $0

Maximum cost per vote for mass mobilization campaign

**Methodology**: [../strategy/roadmap.qmd#vote-acquisition-cost](../strategy/roadmap.qmd#vote-acquisition-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Cost Per Vote Min Usd {#sec-treaty_campaign_cost_per_vote_min_usd}

**Value**: $0

Minimum cost per vote for mass mobilization campaign

**Methodology**: [../strategy/roadmap.qmd#vote-acquisition-cost](../strategy/roadmap.qmd#vote-acquisition-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Duration Years {#sec-treaty_campaign_duration_years}

**Value**: 4

Treaty campaign duration (3-5 year range, using midpoint)

**Methodology**: [../strategy/roadmap.qmd](../strategy/roadmap.qmd)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Total Cost {#sec-treaty_campaign_total_cost}

**Value**: $1.00B

Total treaty campaign cost (100% VICTORY Social Impact Bonds)

$$
CampaignCost = \$0.3B + \$0.65B + \$0.05B = \$1.0B
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-campaign-vs-implementation](../appendix/fundraising-strategy.qmd#capital-structure-campaign-vs-implementation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Total Cost Base Case {#sec-treaty_campaign_total_cost_base_case}

**Value**: $840M

Base case total campaign cost (optimistic viral referendum)

$$
CampaignCost_{base} = \$140M + \$650M + \$50M = \$840M
$$

**Methodology**: [../economics/campaign-budget.qmd#base-case-scenario](../economics/campaign-budget.qmd#base-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Total Cost Realistic {#sec-treaty_campaign_total_cost_realistic}

**Value**: $920M

Realistic total campaign cost (moderate tiered pricing)

$$
CampaignCost_{realistic} = \$220M + \$650M + \$50M = \$920M
$$

**Methodology**: [../economics/campaign-budget.qmd#realistic-scenario](../economics/campaign-budget.qmd#realistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Total Cost Worst Case {#sec-treaty_campaign_total_cost_worst_case}

**Value**: $1.11B

Worst-case total campaign cost (high tiered pricing, poor virality)

$$
CampaignCost_{worst} = \$406M + \$650M + \$50M = \$1.106B
$$

**Methodology**: [../economics/campaign-budget.qmd#worst-case-scenario](../economics/campaign-budget.qmd#worst-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Verification Attempts Multiplier {#sec-treaty_campaign_verification_attempts_multiplier}

**Value**: 1.18

Verification attempts multiplier (1 Ã· conversion rate, assuming 85% completion)

*Formula*: `1 Ã· VERIFICATION_CONVERSION_RATE`

**Methodology**: [../economics/campaign-budget.qmd#verification-cost-analysis](../economics/campaign-budget.qmd#verification-cost-analysis)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Viral Referendum Base Case {#sec-treaty_campaign_viral_referendum_base_case}

**Value**: $140M

Base case viral referendum budget (assumes flat $0.50/vote, optimistic)

*Formula*: `PLATFORM + VERIFICATION + PAYMENTS_FLAT_RATE`

**Methodology**: [../economics/campaign-budget.qmd#base-case-scenario](../economics/campaign-budget.qmd#base-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Viral Referendum Realistic {#sec-treaty_campaign_viral_referendum_realistic}

**Value**: $220M

Realistic viral referendum budget (moderate tiered pricing)

$$
Budget_{realistic} = \$35M_{platform} + \$59M_{verification} + \$126M_{tiered\ payments} = \$220M
$$

**Methodology**: [../economics/campaign-budget.qmd#realistic-scenario](../economics/campaign-budget.qmd#realistic-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Viral Referendum Worst Case {#sec-treaty_campaign_viral_referendum_worst_case}

**Value**: $406M

Worst-case viral referendum budget (tiered pricing with increasing marginal costs)

$$
Budget_{worst} = \$35M_{platform} + \$59M_{verification} + \$312M_{tiered\ payments} = \$406M
$$

**Methodology**: [../economics/campaign-budget.qmd#worst-case-scenario](../economics/campaign-budget.qmd#worst-case-scenario)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Campaign Voting Bloc Target Millions {#sec-treaty_campaign_voting_bloc_target_millions}

**Value**: 280M

Target voting bloc size for campaign

**Methodology**: [../strategy/roadmap.qmd#voting-bloc](../strategy/roadmap.qmd#voting-bloc)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Complete Case Annual Benefits {#sec-treaty_complete_case_annual_benefits}

**Value**: $1.24T

Total annual benefits from all 8 categories (peace dividend + R&D savings + earlier access + research acceleration + rare diseases + drug prices + prevention + mental health)

$$
TotalComplete = \$113.6B + \$50B + \$300B + \$100B + \$400B + \$100B + \$100B + \$75B = \$1,238.6B
$$

**Methodology**: [../economics/economics.qmd#complete-case-roi](../economics/economics.qmd#complete-case-roi)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Lives Saved Annual Global {#sec-treaty_lives_saved_annual_global}

**Value**: 2,446

Annual lives saved from 1% reduction in conflict deaths

$$
LivesSaved = 244,600 \times 0.01 = 2,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#lives-saved](../appendix/1-percent-treaty-cost-effectiveness.qmd#lives-saved)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Net Annual Benefit {#sec-treaty_net_annual_benefit}

**Value**: $139B

Net annual benefit (total benefits - total costs)

$$
NetBenefit = \$163.55B - \$0.29B = \$163.26B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#net-benefit](../appendix/1-percent-treaty-cost-effectiveness.qmd#net-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Qalys Gained Annual Global {#sec-treaty_qalys_gained_annual_global}

**Value**: 85,610

Annual QALYs gained from peace dividend (lives saved Ã— QALYs/life)

$$
QALYs_{peace} = 2,446 \times 35 = 85,610
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-qalys](../appendix/1-percent-treaty-cost-effectiveness.qmd#peace-qalys)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Total Annual Benefits {#sec-treaty_total_annual_benefits}

**Value**: $139B

Total annual benefits (peace dividend + dFDA savings)

$$
TotalBenefits = \$113.55B + \$50B = \$163.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-benefits](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-benefits)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Total Annual Costs {#sec-treaty_total_annual_costs}

**Value**: $290M

Total annual system costs (campaign + dFDA operations)

$$
TotalCosts = \$0.25B + \$0.04B = \$0.29B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-costs](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Total Lives Saved Annual {#sec-treaty_total_lives_saved_annual}

**Value**: 26,446

Total annual lives saved equivalent (total QALYs Ã· QALYs/life)

$$
Lives_{total} = 925,610 / 35 = 26,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-lives)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Treaty Total Qalys Gained Annual {#sec-treaty_total_qalys_gained_annual}

**Value**: 926K

Total annual QALYs gained (dFDA + peace dividend)

$$
QALYs_{total} = 840,000 + 85,610 = 925,610
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness.qmd#total-qalys](../appendix/1-percent-treaty-cost-effectiveness.qmd#total-qalys)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Trial Completion Speed Multiplier {#sec-trial_completion_speed_multiplier}

**Value**: 10

Trial completion speed multiplier (10x faster)

**Methodology**: [../appendix/research-acceleration-model.qmd#completion-acceleration](../appendix/research-acceleration-model.qmd#completion-acceleration)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Type Ii Error Cost Ratio {#sec-type_ii_error_cost_ratio}

**Value**: 1,610

Ratio of Type II error cost to Type I error benefit (harm from delay vs. harm prevented)

$$
\frac{Cost_{delay}}{Benefit_{safety}} = \frac{4.83B}{0.003B} = 1{,}610:1
$$

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#risk-analysis](../appendix/regulatory-mortality-analysis.qmd#risk-analysis)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Type I Error Benefit Dalys Billions {#sec-type_i_error_benefit_dalys_billions}

**Value**: 0.003

Maximum DALYs saved by FDA preventing unsafe drugs (extreme overestimate)

**Methodology**: [../appendix/regulatory-mortality-analysis.qmd#risk-analysis](../appendix/regulatory-mortality-analysis.qmd#risk-analysis)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Funding Base Case {#sec-victory_bond_funding_base_case}

**Value**: $498M

VICTORY Social Impact Bond funding in base case (political lobbying, mobilization)

$$
VICTORY_{base} = \$940M \times 53\% = \$498M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Funding Percentage {#sec-victory_bond_funding_percentage}

**Value**: 49%

VICTORY bond funding as percentage of total campaign cost (realistic scenario)

$$
VICTORY\% = \frac{\$501M}{\$1,020M} = 49\%
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Funding Realistic {#sec-victory_bond_funding_realistic}

**Value**: $501M

VICTORY Social Impact Bond funding in realistic scenario (political lobbying, mobilization)

$$
VICTORY_{realistic} = \$1,020M \times 49\% = \$501M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Funding Worst Case {#sec-victory_bond_funding_worst_case}

**Value**: $664M

VICTORY Social Impact Bond funding in worst-case scenario (political lobbying, mobilization)

$$
VICTORY_{worst} = \$1,206M \times 55\% = \$664M
$$

**Methodology**: [../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions](../appendix/fundraising-strategy.qmd#capital-structure-two-funding-sources-two-missions)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Investment Unit Usd {#sec-victory_bond_investment_unit_usd}

**Value**: $1.00K

VICTORY bond investment unit for retail investors

**Methodology**: [../strategy/roadmap.qmd#victory-bonds](../strategy/roadmap.qmd#victory-bonds)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Bond Payout Per Unit Usd Annual {#sec-victory_bond_payout_per_unit_usd_annual}

**Value**: $2.72K

Annual payout per $1,000 VICTORY bond investment unit

$$
PayoutPerUnit = \frac{\$2.718B}{\$1B} \times \$1,000 = \$2,718
$$

**Methodology**: [../strategy/roadmap.qmd#victory-bonds](../strategy/roadmap.qmd#victory-bonds)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Legal Compliance Realistic {#sec-victory_legal_compliance_realistic}

**Value**: $47M

VICTORY funding for legal/compliance (political campaign compliance)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Lobbying Realistic {#sec-victory_lobbying_realistic}

**Value**: $250M

VICTORY funding for political lobbying (US/EU/G20, Super PACs, opposition research)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Operations Realistic {#sec-victory_operations_realistic}

**Value**: $30M

VICTORY funding for operations (political campaign staff)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Partnerships Realistic {#sec-victory_partnerships_realistic}

**Value**: $71M

VICTORY funding for partnerships (defense industry conversion, political coalitions)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Reserve Realistic {#sec-victory_reserve_realistic}

**Value**: $13M

VICTORY funding for reserve (political campaign contingency)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Tech Rd Realistic {#sec-victory_tech_rd_realistic}

**Value**: $24M

VICTORY funding for technology R&D (political campaign tools)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
## Victory Viral Referendum Realistic {#sec-victory_viral_referendum_realistic}

**Value**: $143M

VICTORY funding for viral referendum (referral payments, political advertising)

**Methodology**: [../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario](../appendix/fundraising-strategy.qmd#detailed-allocation-by-component-realistic-102b-scenario)

*âœ“ High confidence*

:::

# Core Definitions {#sec-definitions}

Fundamental parameters and constants used throughout the analysis.

::: {.callout-warning icon=false collapse=false}
## Caregiver Cost Annual {#sec-caregiver_cost_annual}

**Value**: 6,000

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Caregiver Hours Per Month Avg {#sec-caregiver_hours_per_month_avg}

**Value**: 110

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Defense Sector Retention Pct {#sec-defense_sector_retention_pct}

**Value**: 99%

Percentage of budget defense sector keeps under 1% treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Dfda Patient Eligibility Rate {#sec-dfda_patient_eligibility_rate}

**Value**: 50%

dFDA patient eligibility rate (50% of disease patients can participate)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Dfda Trial Abandonment Rate {#sec-dfda_trial_abandonment_rate}

**Value**: 5%

dFDA trial abandonment rate (5%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Dfda Trial Completion Rate {#sec-dfda_trial_completion_rate}

**Value**: 95%

dFDA trial completion rate (95%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Dih Treasury To Medical Research Annual {#sec-dih_treasury_to_medical_research_annual}

**Value**: $24.5B

Annual funding for medical research (treaty funding minus bond payouts)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Dih Treasury To Medical Research Annual Pct {#sec-dih_treasury_to_medical_research_annual_pct}

**Value**: 90%

Percentage of treaty funding going to medical research (remainder after bonds)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Gdp Growth Boost 10Pct {#sec-gdp_growth_boost_10pct}

**Value**: 0.025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Gdp Growth Boost 1Pct {#sec-gdp_growth_boost_1pct}

**Value**: 0.0025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Gdp Growth Boost 2Pct {#sec-gdp_growth_boost_2pct}

**Value**: 0.005

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Gdp Growth Boost 5Pct {#sec-gdp_growth_boost_5pct}

**Value**: 0.0125

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Infections Death Rate {#sec-infections_death_rate}

**Value**: 15

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 10Pct {#sec-life_extension_years_10pct}

**Value**: 4.12

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 1Pct {#sec-life_extension_years_1pct}

**Value**: 1.15

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 2Pct {#sec-life_extension_years_2pct}

**Value**: 1.48

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Life Extension Years 5Pct {#sec-life_extension_years_5pct}

**Value**: 2.47

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 10Pct {#sec-medical_progress_multiplier_10pct}

**Value**: 412

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 1Pct {#sec-medical_progress_multiplier_1pct}

**Value**: 115

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 2Pct {#sec-medical_progress_multiplier_2pct}

**Value**: 148

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Medical Progress Multiplier 5Pct {#sec-medical_progress_multiplier_5pct}

**Value**: 247

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Npv Discount Rate Standard {#sec-npv_discount_rate_standard}

**Value**: 8%

Standard discount rate for NPV analysis (8% annual)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Npv Time Horizon Years {#sec-npv_time_horizon_years}

**Value**: 10

Standard time horizon for NPV analysis

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Other Death Rate {#sec-other_death_rate}

**Value**: 250

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 20 1Pct {#sec-personal_lifetime_benefit_age_20_1pct}

**Value**: 414K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 10Pct {#sec-personal_lifetime_benefit_age_30_10pct}

**Value**: 3.22M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 1Pct {#sec-personal_lifetime_benefit_age_30_1pct}

**Value**: 402K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 2Pct {#sec-personal_lifetime_benefit_age_30_2pct}

**Value**: 591K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 5Pct {#sec-personal_lifetime_benefit_age_30_5pct}

**Value**: 1.31M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 30 Half Pct {#sec-personal_lifetime_benefit_age_30_half_pct}

**Value**: 247K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 40 1Pct {#sec-personal_lifetime_benefit_age_40_1pct}

**Value**: 369K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 50 1Pct {#sec-personal_lifetime_benefit_age_50_1pct}

**Value**: 301K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Age 60 1Pct {#sec-personal_lifetime_benefit_age_60_1pct}

**Value**: 206K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Conservative Age 30 1Pct {#sec-personal_lifetime_benefit_conservative_age_30_1pct}

**Value**: 584K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Conservative Moderate Age 30 1Pct {#sec-personal_lifetime_benefit_conservative_moderate_age_30_1pct}

**Value**: 901K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 10Yr Age 30 1Pct {#sec-personal_lifetime_benefit_eradication_10yr_age_30_1pct}

**Value**: 1.52M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 20Yr Age 30 1Pct {#sec-personal_lifetime_benefit_eradication_20yr_age_30_1pct}

**Value**: 1.96M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 40Yr Age 30 1Pct {#sec-personal_lifetime_benefit_eradication_40yr_age_30_1pct}

**Value**: 2.61M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Personal Lifetime Benefit Eradication 5Yr Age 30 1Pct {#sec-personal_lifetime_benefit_eradication_5yr_age_30_1pct}

**Value**: 1.18M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Per Capita Chronic Disease Cost {#sec-per_capita_chronic_disease_cost}

**Value**: 12,239

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Per Capita Mental Health Cost {#sec-per_capita_mental_health_cost}

**Value**: 1,045

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Seconds Per Year {#sec-seconds_per_year}

**Value**: 31.5M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Treaty Annual Funding {#sec-treaty_annual_funding}

**Value**: $27.2B

Annual funding from 1% of global military spending redirected to DIH

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Treaty Reduction Pct {#sec-treaty_reduction_pct}

**Value**: 1%

1% reduction in military spending/war costs from treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Trial Cost Reduction Pct {#sec-trial_cost_reduction_pct}

**Value**: 50%

Trial cost reduction percentage (50% baseline, conservative)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Victory Bond Annual Payout {#sec-victory_bond_annual_payout}

**Value**: $2.72B

Annual VICTORY bond payout (treaty funding Ã— bond percentage)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Victory Bond Annual Return Pct {#sec-victory_bond_annual_return_pct}

**Value**: 272%

Annual return percentage for VICTORY bondholders

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Victory Bond Funding Pct {#sec-victory_bond_funding_pct}

**Value**: 10%

Percentage of captured dividend funding VICTORY bonds (10%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
## Victory Bond Payback Months {#sec-victory_bond_payback_months}

**Value**: 4.42

Months to full payback for VICTORY bondholders

*Core definition*

:::
